b e h r n g e r n g e l h e n n u l r e p r value innovationf n ci l h gh l ig h ts um ar r ep r amounts millions eur unless otherwise indicated change net sales region americas europe asiaaustraliaafrica aaa business human pharma summary report animal health biopharmaceutical contract manufacturing discontinued operations research development expenses personnel expenses average number employees operating income operating income net sales group profit net sales group equity return group equity investments tangible assets depreciation tangible assets top products human pharma top products animal health net sales million eur change net sales million eur change jardiance nexgard spiriva frontline trajenta jentadueto heartgard pradaxa ingelvac circoflex flexcombo v e r v e w core leitbild group management report consolidated financial statements product portfolio company making new better medicines humans animals heart mission create breakthrough therapies change lives independent familyowned boehringer ingelheim freedom pursue longterm vision looking ahead identify health challenges future targeting areas need good worldleading researchdriven pharmaceutical company employees create value innovation daily three business areas human pharma animal health biopharmaceutical contract manufacturing boehringer ingelheim achieved net sales billion euros significant investment almost billion euros rd drives innovation enabling next generation medicines save lives improve quality life realize scientific opportunities embracing power partnership diversity experts across lifescience community working together accelerate delivery next medical breakthrough transform lives patients generations comec n e n core leitbild shareholders perspective key aspects corporate bodies group management report information group report economic position report opportunities risks report expected developments consolidated financial statements overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial tatements independent auditors report product portfolio human pharmaceuticals respiratory diseases cardiovascular metabolic diseases oncology diseases central nervous system infectious diseases animal health livestock swine livestock cattleruminants livestock poultry veterinary public health vph companion animals horse companion animals pets boehringer ingelheim annual report shareholders perspective shareholders perspective look back successful financial year boehringer ingelheim made another important contribution human animal health medicines improved quality life given patients years live possible relied power innovation many decades invest sustainably continuously increasing extent innovative strength basis companys independence reach patients need competitive offer need fulfil promise quality convince value contribution past years done well special year shareholders well company especially many colleagues involved making health mmh initiative mmh celebrating tenth anniversary year since foundation mmh making important contribution improving healthcare people worldwide c urrently social entrepreneurs active mmh network around countries impressive record young initiative timeless mission sincere thanks go employees together great personal commitment contributed development boehringer ingelheim past year laid foundation successful future signed christian boehringer chairman shareholders committeethe board managing directors michel pairet carinne brouillonthe board managing directors hubertus von baumbach michael schmelmer jean scheftsik de szolnok boehringer ingelheim annual report learn every day personal environment media great need innovative medicines new therapies urgently needed whether common diseases rare affect lives health boehringer ingelheim set goal making decisive contribution improving human animal health task inspires drives us every day focus diseases great medical need due lack therapeutic options outbreaks african swine fever covid remind us pharmaceutical progress human veterinary medicine continues highly important society take advantage advances science offer new approaches rely strengths developed years company history human pharma business working clinical preclinical research development projects involving new active ingre dients last year ten active ingredients tested clinical environment first time percent active ingredients pipeline come collaboration exter nal researchers bridging gap industry science essential us research collaborate projects around academic institutions three continents example since funded basic biomedical research research institute molecular pathology imp vienna imp enjoyed excellent reputation decades drugs help save human lives example assumed launch jardiance extend lives type diabetes patients treated million patientyears continue treatment also actilyse remains vital irreplaceable medicine millions stroke patients worldwide years since market launch besides development innovative active ingredients topic sustainability plays increasingly important role drug development last year launched reusable respimat inhaler respiratory products spiriva spiolto reusable respimat eliminate metric tons plastic waste metric tons co emissions key aspects area animal health consequences african swine fever hit customers china particularly hard unfortunately insidious virus development vaccine challenging takes long time facing challenge together p artners china europe way new products initiated clinical trials worldwide last year received product approvals including articell forte europe first stem cellbased veterinary therapy treatment lameness horses boehringer ingelheim strong yet flexible production network within network pro duction medicines europe also continues play important role order remain com petitive long term current investment program expansion european produc tion facilities volume one billion euros year inaugurate new production facility biopharmaceutical products vienna single largest capital investment ever made company plan use facility production portfolio third party contract manufacturing important milestone bio pharmaceutical contract manufacturing also first market approval biologic produced boehringer ingelheim shanghai chinese market successful year terms performance enabled us strengthen basis independence allowed investments innovation rd urgently needed drugs well capital investments would like thank customers trust partners support spe cial thanks go employees laid foundation success past year future often pioneers respective fields together share goal make contri bution human animal health signed signed signed hubertus vo n baumbach carinne brouillon michel pairet signe signe jean scheftsik de szolnok michael schmelmer corporate bodies shareholders committee board managing directors christian boehringer hubertus von baumbach chairman shareholders committee chairman board managing directors christoph boehringer carinne knochebrouillon member board managing directors erich von baumbach jr human pharma isabel boehringer dr joachim hasenmaier member board managing directors dr mathias boehringer animal health prof dr dr andreas barner allan hillgrove member board managing directors human pharma advisory board dr andreas neumann member board managing directors egbert appel human resources chairman advisory board trustee martin hilti family trust dr michel pairet president hilti foundation member board managing directors innovation dr nikolaus von bomhard chairman advisory board jean scheftsik de szolnok chairman supervisory board member board managing directors mnchener rckversicherungsgesellschaft ag animal health dr andreas kreimeyer michael schmelmer former member board executive directors member board managing directors research executive director basf se finance finance group functions dr frank mastiaux chief executive officer ceo enbw energie badenwrttemberg ag jan rinnert chairman board managing directors ceo heraeus holding gmbhpage g r u p n g e e n r e p r information group groups business model research development production sustainability occupational safety environmental protection employee reporting social responsibility report economic position macroeconomic environment earnings position development businesses financial position net assets position report opportunities risks opportunities risk management individual risks overall statement risk situation report expected developments troper tnemeganam puorg boehringer ingelheim annual report group management report information group groups business model foundation years ago boehringer ingelheim developed researchbased pharmaceutical company headquartered ingelheim rhein germany company familyowned since founding among worlds leading pharmaceutical compa nies aim business activities sustainably improve health quality life humans animals one germanys researchintensive companies boehringer ingelheim concen trates researching medicines offering therapies diseases satisfactory treatment options currently unavailable provides entire value chain research development rd production commercialization products global level every day employees create value innovation companys three businesses human pharma animal health biopharmaceutical contract manufacturing boehringer ingelheim generated net sales billion eur businesses share overall sales human pharma business core focus boehringer ingelheims activities numerous companys products already standard treatments medicine jardiance strongest human pharma business developed positively financial year first time revenue contributor strongest revenue contributor segment jardiance medicine treatment type diabetes first time also reduces risk cardiovascular diseases type diabetics preexisting cardi ovascular conditions following medicines also played significant role boehringer ingelheims success spiriva treatment chronic obstructive pulmonary disease copd well unmesta tszearllsees n abchy g besuchsifntene sins group million eur biopharmaceutical contract manufacturing sales million eur million eur animal health human pharma million eur million eur group management report information group net sales region million eur europe asia australia africa aaa americas asthma pradaxa used prevent strokes patients atrial fibrillation pre vention treatment thromboembolic disorders trajenta used treatment type diabetes ofev used treatment rare fatal respiratory disease idiopathic pulmonary fibrosis ipf increasingly also indication systemic sclerosis intersti tial lung disease sscild likewise provided significant contribution companys growth boehringer ingelheims animal health business one biggest providers veterinary vaccines medicines strong presence livestock pets segments mergers world market resulted consolidation animal health market boehringer ingelheim market leader germany secondlargest provider global level net sales increased pets segment sales plunged swine segment due outbreak african swine fever especially china significant products terms net sales include antiparasitics nexgard heartgard frontline established swine vaccine ingelvac circoflex used treat porcine circovirus type biopharmaceutical contract manufacturing another important growth area boehringer ingelheim boehringer ingelheims biopharmaceutical activities comprise manufacture brand marketable products actilyse metalyse praxbind one worlds leading providers process development commercial production biopharmaceuticals third party industrial customers sales mainly comprise discontinued operations financial year boehringer ingelheim achieved majority sales americas europe regions region asiaaustraliaafrica aaa countries china reported currencyadjusted sales growth human pharma business strategic ignificance groups future development making sales laicnanif detadilosnoc stnemetats boehringer ingelheim annual report research development line mission statement boehringer ingelheims goal research develop innovative medicines therapies treatment diseases yet satisfactory treat ments available major emphasis development medicines well new approaches therapies prevent detect treat chronic diseases areas need treatment high want make major contribution human pharma business well field animal health global research network countries major facilities germany biberach hanover ingelheim usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon boehringer ingelheim continues explore opportunities expanding existing product portfolio organic growth including cooperation external partners build cooperation academic institutions biotech companies public research institutions global research network comprising facilities moreover research activities rd expenses field development projects technologies supplemented important cooperation increased license agreements key component boehringer ingelheims innovation strategy supple net sales mentation broad rd portfolio partnerships especially scientific area collaborate active projects academic institutes spanning three continents strengthen groups innovative prowess human pharma aiming least new molecules pipeline come external innovation research development expenses million eur net sales human pharma expenses million eur human pharma net sales animal health expenses million eur animal health net sales average number employees investments tangible assets without investments infrastructure million eur boehringer ingelheim expanded research network purchase shares swiss biotech company amal therapeutics sa concentrates cancer immunotherapy research network develops innovative therapeutic cancer vaccines acquisition important step strengthening expanded boehringer ingelheims position research immunooncological cancer therapies boehringer ingelheim also agreed collaborate south korean pharmaceutical company yuhan corpo ration treating nonalcoholic steatohepatitis nash cooperation license agreement focuses therapy three main causes diseases steatosis inflammation scarring group management report information group rd sites animal health ah human pharma hp americas europe asia oceania brazil germany australia paulnia ah biberach hp sydney ah hanover ah mexico ingelheim rhein ah china g uadalajara tateposco ah katharinenhofrohrdorf ah beijing ah shanghai ah usa france taizhou ah ames ah lyon ah athens colbert ah saintvulbas ah japan uluth ah kobe hp f ulton ah netherlands tokyo ah gainesville ah lelystad ah n orth brunswick ah new zealand ridgefield hp austria auckland ah saint joseph ah innsbruck hp sioux center ah vienna hp switzerland geneva hp bi x boehringer ingelheims digital laboratory grew employees past year agile development teams transferred several innovative digital products companys businesses exam ples farmera platform helps swine farmers keep livestock healthy thus enhances productivity smart employs selflearning algorithms increase efficiency biopharmaceutical production lines laicnanif detadilosnoc stnemetats boehringer ingelheim annual report since boehringer ingelheim venture fund drives innovation strategic invest ments earlystage science technology venture fund invests biotech startup compa nies innovative concepts technologies potential provide groundbreaking therapeutic platforms venture fund also creates companies identifies promising research projects universities academic institutions biomedical research institute imp vienna austria largely funded boehringer ingelheim scientists countries carry research molecular cellular mechanisms form basis complex biological phenomena boehringer ingelheims rd activities basis companys sustainable success innova tive capability played key role groups positive business development past years inhouse rd supplemented external cooperation partnerships also continue top priority future financial year employed average people rd facilities total almost billion eur invested research development new medicines level corresponds around groups net sales human pharma new century committed improving lives patients focus substances human pharma rd lies cardiovascular metabolic diseases oncology respiratory diseases human pharma portfolio immunology diseases central nervous system cns retinal health end new substances included human pharma development portfolio around clinical preclinical projects working development registration selection important research development projects shown hereinafter development pipeline end phase cardiovascular metabolic diseases glpr gcgr agonist phase amylin analog phase hemodynamic modulator phase empalinamet xr combination empaglifozin linagliptin und metformin registration approval appetite modulator phase empagliflozin new indication phase iii sglt inhibitor tdm empagliflozin new indication phase iii sglt inhibitor ckd empagliflozin new indication phase iii sglt inhibitor chf group management report information group development pipeline end phase oncology pd antibody phase mrna vaccine phase vegfang antibody phase lag antibody phase smacmimetic phase bet inhibitor phase lrp inhibitor phase mdmp antagonist phase sirp antagonist phase soskras inhibitor phase mek inhibitor phase recombinant vaccine phase xentuzumab bi phase ii igf antibody mbc respiratory diseases autotaxin inhibitor phase nonreceptor tyrosine kinase inhibitor phase cysteine protease inhibitor phase leukocyte protease inhibitor phase phosphodiesterase inhibitor phase bi phase ii enac inhibitor cf nintedanib new indication registration triple angiokinase inhibitor pfild approval nintedanib new indication registration triple angiokinase inhibitor sscild approval immunology nuclear receptor antagonist phase epithelial barrier stress modulator phase receptor serinethreonine kinase inhibitor phase spesolimab bi phase ii ilr antibody gpp spesolimab bi phase ii ilr antibody ppp spesolimab bi phase ii ilr antibody atd spesolimab bi phase ii ilr antibody ulcerative colitis spesolimab bi phase ii ilr antibody cd crohns disease bi phase ii nuclear receptor antagonist psoriasis laicnanif detadilosnoc stnemetats boehringer ingelheim annual report development pipeline end phase central nervous system diseases trpc inhibitor phase bi phase ii pde inhibitor fep bi phase ii pde inhibitor rex bi phase ii glyt inhibitor cias bi phase ii glyt inhibitor ad retinal health neuronal damage modulator phase vegf ang antibody phase bi phase ii aoc inhibitor diabetic retinopathy indication abbreviations ad alzheimers disease ckd chronic kidney disease rex r eduction relapse atd atopic dermatitis fep first episode psychosis schizophrenia cd crohn 's disease gpp generalized pustular psoriasis sscild ystemic sclerosis associated interstitial cf cystic fibrosis mbc metastatic breast cancer lung disease chf congestive heart failure pfild p rogressive fibrosing tdm type diabetes mellitus cias c ognitive impairment interstitial lung disease schizophrenia ppp palmoplantar pustulosis partnered projects acquired assets study complete submissions ongoing key pipeline advances aprildecember approved us systemic sclerosisassociated ild boehringer ingelheims therapeutic area cardiovascular metabolic diseases contains companys core products within diabetes portfolio alliance eli lilly important research data published heart failure progressive debilitating potentially fatal condition leading cause hospi talization europe us half people heart failure expected die within five years diagnosis boehringer ingelheim eli lilly alliance announced initiation empulse sixth phase iii study empagliflozin heart failure program also consists emperorreduced emperorpreserved emperialpreserved empavision studies studies investigating effects empagliflozin heart failure related outcomes functional capacity patients heart failure including without type diabe tes building legacy innovative treatments range cardiovascular metabolic condi tions rd strategy takes holistic view needs cardio metabolic disease patients often multiple related conditions pursuing next wave innovative medicines obesity kidney liver diseases including nonalcoholic steatohepatitis nash group management report information group focus oncology research take cancer developing novel therapeutic approaches address unmet needs lung gastrointestinal cancers advancing broad pipeline cancer celldirected agents immune oncology therapies combinations approaches successfully advanced range research programs area ten new development projects tested people first time scientific research new therapeutic concepts help patients respiratory diseases continues high importance boehringer ingelheim focus areas leveraged extensive expertise respiratory medicine inflammation fibrosis target broad range inter stitial lung diseases including indications ipf systemic sclerosisassociated interstitial lung disease sscild well serious lung diseases high unmet need cystic fibrosis severe asthma data readouts two phase iii data sets nintedanib sscild sencsis trial progressive fibrosing interstitial lung diseases pfild inbuild trial occurred based upon data filings regulatory approvals respective indications submitted first approvals ofev slow rate decline pulmonary function patients sscild granted us japan countries new respimat reusable launched first countries boehringer ingelheim continuously developing immunology rd activities years ramping capacities series dermatological gastroenterological indications last year risankizumab originally discovered research activities partnered abbvie received marketing approval commercialized abbvie major geographies important neuropsychiatric diseases schizophrenia depression continue center boehringer ingelheims research central nervous system diseases whilst medical need high number patients increasing scientific challenges extremely high boehringer ingelheim takes challenge remains optimistic develop effective therapies treatment neuropsychiatric diseases clinical investigation program also encompasses aspect early treatment options point symptoms physical disor ders disturbing yet pronounced could potentially detected eg voice analysis could favorably impact avoid dramatic development boehringer ingelheim also expanded global research development activities tackle boehringer ingelheim eye diseases specifically affecting back eye science innovation core extends research comprehensive pipeline portfolio company built retinal health first assets spectrum retinal health already clinical development aim prevent visual impairment blindness effective possible addition building strengths core therapeutic areas capture synergies focusing research platforms ofev good example areas immune modulation fibrosis working combining new approaches focus common pathophysiological mecha nisms enables us discover new approaches accelerate development new medicines laicnanif detadilosnoc stnemetats boehringer ingelheim annual report following table shows relevant changes current clinical studies phase iii clinical trial phase changes senscis nct double blind phase iii study completed met primary endpoint randomized placebocontrolled trial evaluating published new england journal medicine efficacy safety oral nintedanib treatment phase iii senscis trial nintedanib least weeks patients systemic slowed loss pulmonary function sclerosisassociated interstitial lung disease patients sscild compared placebo sscild patients taking nintedanib showed reduction rate decline lung function measured fvc assessed weeks inbuild nct double blind phase iii study completed met primary endpoint randomized placebocontrolled trial evaluating published new england journal medicine efficacy safety nintedanib phase iii inbuild trial nintedanib weeks patients progressive fibrosing slowed lung function decline significantly interstitial lung disease pfild across overall study population assessed annual rate decline forced vital capacity fvc weeks patients fibrosing interstitial lung dis ease ilds signs progression openlabel longterm extension study phase iii first patient included assess safety efficacy bi spesolimab treatment patients general ized pustular psoriasis gpp took part previous studies bi empakidney nct multinational phase iii first patient included randomized doubleblind placebocontrolled clinical trial designed evaluate effect empagliflozin kidney disease progression cardiovascular mortality risk people preexisting chronic kidney disease without type diabetes carolina nct multinational phase iii study completed met primary endpoint randomized doubleblind placebocontrolled published journal american medical clinical trial designed assess effect lina association gliptin compared glimepiride cardiovascular cv safety adults relatively early type diabetes increased cv risk established cv disease group management report information group animal health rd activities field animal health boehringer ingelheim concentrates innovative vaccines antiparasitics protection livestock pets well pharmaceutical products treatment chronic diseases goal strengthen animal health means innovative preventive solutions medicines globally oriented research development facilities focus research new sub stances development future therapeutic solutions since many vaccines based local pathogens pathogen variants imperative present key market regions local rd production facilities past year created comprehensive database pet livestock diseases serve basis focusing research development activities diseases clinical symptoms entered database evaluated based various key criteria pathogens affected organ systems addition brought articell forte first stem cellbased animal health product onto launch european market used treat lameness horses also continue work highly articell forte promising innovative digitally integrated diagnostics solutions initiated clinical studies worldwide received product authorizations addition internal research development analyze external projects products integrate portfolio appropriate obtaining approvals expanding geographical distribution existing products important aspects rd activities laicnanif detadilosnoc stnemetats boehringer ingelheim annual report production facilities animal health ah human pharma hp biopharmaceutical contract manufacturing bio americas europe italy asia oceania brazil denmark fornovo hp china itapecerica hp kalundborg ah noventa ah nanchang ah paulnia ah shanghai hp bio germany netherlands taizhou ah mexico biberach bio lelystad ah guadalajara ah dortmund hp indonesia xochimilco hp ingelheim rhein hp austria bogor hp vienna bio puerto rico france japan barceloneta ah lyon ah spain yamagata hp toulouse ah sant cugat hp usa new zealand athens ah greece united kingdom auckland ah fremont bio koropi hp pirbright ah gainesville ah st joseph ah worthington ah production human pharma human pharma business production responsible reliable supply innovative topquality medicines competitive prices patients customers ongoing development companys internal production facilities strategic cooperation external manufacturers established modern flexible market supply network encompasses entire value chain suppliers starting materials worldwide logistics distribution finished pharmaceu tical products boehringer ingelheims production facilities concentrate products strategi cally important company well stateoftheart cases unique manufacturing technologies partnerships external manufacturers expand production capacities particularly products already far advanced terms life cycle group management report information group financial year global network included boehringer ingelheims plants nine coun tries group four biopharmaceuticals facilities also two facilities manufacture pharmaceutical active substances one produces medical devices eight manufacture finished pharmaceutical products groups network optimized facility malgrat spain sold assigning important steps technologies within production processes one facility boehringer ingelheim always able ensure patient care delivery capacity patient care high priority boehringer ingelheim company consist ently makes important investments development transformation production capaci ties internal external network ingelheim headquarters boehringer ingelheim made significant progress implementation key investment industrialization newly developed innovative medicines initial supply market construction plant groups sant cugat facility spain completed schedule companys mar kets additionally supplied respimat technologybased inhalation medicines extension biopharmaceutical site vienna austria also creates additional inhouse capacities cover increasing demands actilyse praxbind ongoing implementation groups supply chain strategy optimizing value chain management significantly supplier customer endtoend use modern digital automated processes technologies facilitates transparent efficient management integrated flexible supply chain based global production network animal health animal health products manufactured worldwide sale network animal health production facilities eleven countries addition boehringer ingelheims internal facili ties company used around contract manufacturers manufacture products boehringer animal health ingelheim companys product portfolio essentially unchanged well balanced production facilities vaccines pharmaceutical products nutraceuticals traditional products supplemented eleven countries diagnostics products well monitoring solutions including digital applications used livestock monitoring link livestock owners veterinarians optimization companys production network continues remains priority goal ensuring robust efficient supply products company sold facility saintherblon france reduced number contract manufacturers investments made capacity expansion strongest revenue contributor nexgard barceloneta puerto rico facility expansion small animal vaccine produc tion companys facility athens georgia usa cattle vaccine production st joseph missouri usa capacity expansion footandmouth disease vaccines lyon france additional investments made development innovative technologies manufacture products biopharmaceutical contract manufacturing boehringer ingelheim pursues biopharmaceutical activities facilities biberach germany one leading vienna austria fremont california usa shanghai china comprise manufacture providers ownbrand marketable products actilyse metalyse praxbind manufacture industrial customers biopharmaceuticals clinical testing one worlds leading companies process devel opment launch preparation commercial production biopharmaceuticals thirdparty indus trial customers top pharmaceutical companies innovative biotech firms clients laicnanif detadilosnoc stnemetats boehringer ingelheim annual report boehringer ingelheims biopharmaceutical contract manufacturing business boehringer ingelheim covers entire biopharmaceutical value chain genetic development production cell followed manufacturing active substance filling finished pharmaceutical product product launch global market supply saw overall increase full use capacity network industrialscale production facilities besides many products biberach facility fulfilled increasing market demand actilyse companys facility fremont california usa approval process custom ers market product successfully completed thus possible meet rising product demand within network biberach fremont moreover largescale cell culture plant biberach largescale microbial plant vienna three customer products successfully approved international authorities one products plasmid dna used gene therapy vienna facility boehringer ingelheim actively examining new therapy options expansion project new industrialscale biopharmaceutical production facility boehringer ingelheims facility vienna reached milestone two key functions went operation strategic relevance biotechnological production capacities rising context increasing importance nbes new biological entities pipeline production delivery everything hospital products finished pharmaceutical products began scheduled shanghai china local market countries outside china addition application approval customer product chinese authorities successfully completed first biopharmaceutical product approved line new regulatory requirements contract manufacturing china approval final milestone pilot project boehringer ingelheim chinese regulatory authorities principles cooperation marketing authorization holder contract manufacturer evaluated successfully applied facility shanghai recognized contract manufacturer cmo chinese authorities sustainability occupational safety environmental protection protection employees environment well sustainable use natural resources promotion environmental awareness major components companys mission statement prime importance boehringer ingelheim compliance social environ mental aspects firmly anchored corporate philosophy many years ensure achieve sustainability future generations groupwide company developed binding standards terms environmental protection health safety work internal guidelines reflect respective countryspecific require ments many cases go far beyond standards prescribed law particular follow international standards guidance documents work close cooperation relevant associations within boehringer ingelheim corporate department environment health safety sustainability ehss responsible strategic focus group management report information group started green future choice program developed setting new strategic global goals taking business growth account program optimize green activities facilities business areas worldwide factor ing value chain program considers many different environmental aspects building facil ities close nature provide habitats variety plants animals encouraging green behavior employees adopting measures avoid water air pollution using renewable energy reducing waste creating environmentally friendly products well implementing certi fied systems environmental protection energy management continuously working co reducing measures facilities aiming lower absolute co emission focus sustainability major projects spending additional million eur per year invest green future foster environment friendly energysaving investments means digitalized solutions work implementing globally efficient processes stand ardized software solutions global digitalization projects collection environmental data groupwide green program electronic signature solutions ehs audit systems successfully supported tested implemented digitalization approach enables us rationalize activities throughout world reduce expenditure without suffering quality performance losses boehringer ingelheim aware need active water management programs access suffi ciently clean water impact social cultural justice ecological sustainability commer cial benefits therefore introducing water management programs facilities prone water risk reducing volume medicines left production wastewater require suppliers year october promeco production facility xochimilco mexico awarded alliance water stewardship aws certification boehringer ingelheim first pharma ceutical company worldwide certified globally recognized standard antimicrobial resistance amr poses increasingly serious threat global public health requires action every level government well businesses society large reason boehringer ingelheim joined amr industry alliance one largest private coalitions established offer sustainable solutions combating antimicrobial resistance boehringer ingelheim supports objectives nagoya protocol concerned aspects biodiversity relevant activities pharmaceutical sector commit ted upholding obligations result acceptance nagoya protocol pursuing research development responsible manner safe zero choice program aims reduce number years safe zero workplace accidents celebrated tenth anniversary germany addition high five choice safety initiative intended promote occupational safety introduced laicnanif detadilosnoc stnemetats boehringer ingelheim annual report employee reporting growing number boehringer ingelheim employed people average worldwide represents employees increase previous year number staff increased regions average number employees region americas europe asia australia africa aaa methodology used calculate average number employees revised consolidated financial statements calculated average originally based four previous endofquarter figures changed assessment based monthend figuresthe figures adjusted line new methodology major success factor positive growth group engaged motivated staff accord ingly particularly committed actively developing supporting employees order best prepared challenges ahead part comprehensive training system empha size acquisition technical expertise also promote social skills integration various experiences cultural backgrounds personalities boehringer ingelheim creates openness different approaches opinions living corporate vision value innovation global company important us diversity custom ers reflected workforce creating working environment embraces diversity differ ences one pillars boehringer ingelheim 's corporate culture contributing factor companys success addition competitive salaries boehringer ingelheim offers benefits employees benefits include range company pension plans flexible homebased work options numerous healthrelated benefits significant segment corporate strategy part human resources departments scope ensure employability staff promote wide range opportunities innovation work support employees nurture talents develop individuals vocational training always major importance boehringer ingelheim part standing social responsibility company offers career opportunities great number young people time also tie talented wellqualified workforce young professionals company backdrop demographic change young professionals started careers boehringer ingelheim germany different scientific technical com mercial fields training dualstudy courses average young people enrolled vocational training program group management report information group one companys aims strengthen appeal boehringer ingelheim top employer current future employees boehringer ingelheim received top employer award area auditors international independent top employers institute addition germany boehringer ingelheim also received award argentina brazil china italy indonesia colombia malaysia austria philippines poland romania russia singapore spain south korea thailand vietnam social responsibility boehringer ingelheim powered people therefore actively promote diverse coop erative open working environment employees differences valued respected diversity makes right mix inclusion brings best results mix since concentrate encouraging respectful environment comprehensive diversity inclusion action plan place promote diversity parameters necessary core issues included many activities diversity networks new recommendations respect ful communication boehringer ingelheim official member diversity charter since early proutemployer acknowledged prout work foundation since taking social responsibility important aspect corporate culture commitment wellbeing patients employees well families focus wide range projects important us become involved social interaction within regions active company main focus social engagement support people need help centered human person boehringer ingelheims activ ities also focus protecting maintaining environment major pillar social commitment making health mmh initiative since start continuously developed social entrepreneurship movement within company externally socially entrepreneurial sustainable activities limited indi vidual projects relating various regions issues instead initiative focuses creatively connecting local international partners different sectors networking across tra ditional visible invisible borders central element successful social movement order identify promote implement innovative solutions farreaching complex challenges healthcare sector cocreation bridge social commercial entrepreneurship brings together social entrepreneurs nonprofit organizations health care sector boehringer ingelheim employees resources date within mmh network boehringer ingelheim ashoka one worlds largest nonprofit organizations together helped around social entrepreneurs reach approximately million people worldwide area health care laicnanif detadilosnoc stnemetats boehringer ingelheim annual report mmh initiative also aims promote employees commitment social entrepreneurship order advance health care projects many different countries working local external partners well colleagues throughout boehringer ingelheim mmh leadership programs rural southern india insights india well kenya insights kenya participation social intrapreneurship online courses opportunities collaborate social entrepreneurs mmh network executives residence internal competition promoting employees projects honed staffs social entrepreneurial thinking activities also strengthened networking philosophy partnerships nonprofit organizations social enterprises health care sector large number local projects taken shape employees actively involved improving health means understanding peoples environment everyday challenges offering solutions needed health awareness affordability accessibility health services acceptance play key role mmh plays role university sector goal helping students lecturers learn socially entrepreneurial thinking practical activities develop ment health carerelated projects optimize stroke care europe emerging markets boehringer ingelheim established angels initiative together european stroke organisation eso world stroke organization wso stroke alliance europe safe many national stroke associations compa nies initiative achieved goal developing network clinics europe ensure stroke patients treated line defined standards worldwide already clinics countries support boehringer ingelheim supports german center infection research dzif project develop covid medication therapy new coronavirus sarscov development monoclonal antiviral bodies development aiming complete molecule discovery efforts within six months boehringer ingelheim continued pursue lastmile program support global alliance livestock veterinary medicines galvmed funding bill melinda gates foundation integrated solutionoriented initiative aims respond critical challenges field animal health ensuring consistent availability medical resources animals hard toaccess areas subsaharan africa project boehringer ingelheim helps small farmers gain access veterinary medicines local level also newly approved medicines new employ ment opportunities technical regulatory fields positive effect wellbeing animals people lastmile countries underlines boehringer ingelheims strong social commitment aim positive impact human animal lives areas particularly vital need beyond employees getting involved large variety local initiatives together company order help people need case environmental catastrophes everyday situations providing technical support time providing medical nursing care group management report report economic position report economic position macroeconomic environment world economy suffered noticeable loss momentum past year world economic growth rate almost recorded lowest level since financial economic crisis trade policy tensions us china united kingdoms brexit negotiations eu growing global uncertainty domestic international political measures prompted uncertainty among investors resulted strong decrease investment activity growth slowdown affected advanced economies emerging economies equal measure although significance individual countries varied depending nature trading activities overall conditions direct stronger impact cyclical industries pharmaceu tical markets characterized rather performance capability national economies par ticular demographic development societies global pharmaceuticals market registered growth rate financial year source iqvia trend driven rising demand industrialized countries innovative medi global pharmaceutical cines due aging population industrialized nations better access medical care market continues industrys growth remained positive surpassed figure previous year grow growth healthcare costs percentage gross domestic product many countries means governments payors pressure control regulate healthcare expenditures even strongly past along sustained public political pressure contain prices pharmaceuticals many costcutting measures imposed governments payors include governmentimposed industrywide price reductions mandatory reference price sys tems payors limiting access treatments based strict costbenefit analyses imports medicines lowercost countries expensive ones shift burden payment patients higher copayment programs mandatory substitution generics patented equivalent furthermore protection intellectual property patents etc increasing pressure animal health industry focusses livestock pets growth path particular emerging markets due population growth improving living standards many people animal health market characterized rising demands animal proteins increasing popularity pets hand challenges well strategic growth requires constant research development innovations brought market addition consolidation mergers suppliers well customer side currently leads increasing competition boehringer ingelheim responded environment boldness innovative spirit remains determined improve human animal health even difficult times laicnanif detadilosnoc stnemetats boehringer ingelheim annual report international monetary fund oecd expect world economy register growth rate similar continued loose monetary policy leading central banks preliminary partial agreement trade conflict us china point stabilization united kingdoms expected orderly withdrawal eu also positive impact ever also many risks realized could lead weaker growth include particu lar recently emerged viral disease covid coronavirus could drastic consequences people world economy repeated escalation trade dispute worsening geo political tensions spillover industrial sectors weakness overall economy weather related natural disasters due global activities boehringer ingelheim depending currency developments particular regarding usd japanese yen addition chinese renminbi increases importance currencies major significance boehringer ingelheim positive impact sales past year significant currency risks hedged suitable financial instruments currency development effect net sales average rate basis eur million eur us dollar japanese yen chinese renminbi earnings position guiding principle value innovation longterm corporate strategy intended secure companys independence improving human animal health based new futureoriented therapies areas high medical need core boehringer ingelheims strategic focus requires stable earnings position solid financing base near term boehringer ingelheim recorded net sales million eur financial year corre sponds increase compared previous years level million eur billion eur sales exchange rate development foreign exchange markets associated exchange rate effects positive impact sales trend adjusted effects group grew sales million eur share around overall sales americas region remains boehringer ingelheims key sales market americas region sales increased yearover year currencyadjusted sales europe region rose million eur currencyadjusted group thus achieved sales region growth driven markets germany spain great britain well russia poland french market unable match previous years sales volume asiaaustraliaafrica aaa region also realized strong growth currencyadjusted revenues million eur generated region corresponding share groups total revenues strategically important chinese market provided companys overall sales volume represents currencyadjusted increase yearoveryear growth animal health business china negatively affected outbreak african swine fever group management report report economic position net sales region million eur currency change adjusted americas growth europe regions asiaaustraliaafrica aaa supported good results clinical trials well cooperations external partners placed new products market successfully pushed ahead wellestablished products human pharma business hand results animal health business nega tively affected outbreak african swine fever asia particular also increasing consoli dation animal health industry key figures million eur change net sales operating income return net sales income taxes income taxes materials ratio taking consideration change inventory rose slightly mainly attributable increased destruction costs due african swine fever personnel expenses rose disproportionately slower rate revenues also related high extraordinary effects previous year companys workforce increased particularly strategic facilities amortization depreciation increased comparison past financial year item included adjustments intangible fixed assets human pharma animal health businesses well impairments losses tangible fixed assets operating expenses rose disproportion ately due increased investment research development services purchased projects higher currency losses also hedging yearoveryear operating income included extraordinary effects resulting impairment losses intangible fixed assets restructuring measures integration costs well reversals provisions amounting total million eur million eur previous years operating income surpassed thanks primarily positive operating trend human pharma busi ness boehringer ingelheim recorded operating income million eur corresponding return sales income taxes increased due higher operating income financial income financial income remains strongly adversely affected due decline discount rate pensions similar obligations amounts million eur financial income improved overall due gains plan assets cover pensions similar obligations laicnanif detadilosnoc stnemetats boehringer ingelheim annual report income taxes significantly higher previous year reflected favorable course business pointed previous year particularly burdened strong aperiodic tax expenses must noted regard provisions german commercial law shareholders personal taxes arising group business activities may recognized tax expenses instead taxes presented part withdrawals group equity taking specificity account actual tax ratio markedly higher figure shown profit loss statement despite challenging market conditions business areas boehringer ingelheim group regis tered positive performance financial year following group profit million eur million eur previous year figure increased considerably amounted million eur group profit development businesses past financial year boehringer ingelheims activities divided human pharma animal health biopharmaceutical contract manufacturing businesses net sales businesses million eur currency change adjusted human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations human pharma around total group revenue human pharma main pillar boehringer ingel heims business activities human pharma sales amounted million eur equivalent growth currencyadjusted compared previous year pos human pharma grows itive sales trend resulted solid market position established medicines yet driven regions well products jardiancefamily ofev company achieved growth yearover year regions despite price pressure particularly established medicines boehringer ingelheim successfully held continued pursue reorganization human pharma product portfolio planned type diabetes medicine jardiance companys biggest revenue contributor first time achieved sales million eur jardiance reporting period corresponds increase compared previous years million eur boehringer ingelheims secondstrongest product terms sales past year spiriva used treat chronic obstructive pulmonary disease copd generated sales volume million eur lower previous years level million eur expected view products life cycle group management report report economic position trajenta jentadueto treatment type diabetes registered sales volume million eur growth rate financial year anticoagulant pradaxa achieved increase previous years figure million eur sales volume million eur medicine remains one boehringer ingelheims biggest revenue contributors ofev registered growth rate contributed million eur companys successful sales result product used treatment idiopathic pulmonary fibrosis increasing extend also sscild micardis used treatment high blood pressure recorded growth despite increas ing generic competition product family achieved sales million eur million eur actilyse able increase sales million eur million eur since launched patients benefiting medication despite lost patent protection decade ago biopharmaceutical remains available option immediate treatment cases ischaemic stroke worldwide risankizumab medication treatment plaquepsoriasis mainly developed boehringer ingelheim marketed globally partner abbvie brand name skyrizi net sales million eur change jardiance spiriva trajenta jentadueto growth jardiance pradaxa regard regional distribution revenues human pharma business usa largest market share boehringer ingelheim generated sales mil lion eur corresponds increase compared previous year currency adjusted eucan region europe canada australia new zealand secondbiggest market accounted revenues million eur sales increased compared million eur exchange rate effects significant influence sales trend laicnanif detadilosnoc stnemetats boehringer ingelheim annual report strong sales increase past year companys emerging markets registered strong sales growth currency companys adjusted peoples republic china key driving force region emerging markets currencyadjusted growth rate sales rose million eur previous year million eur japan sales increased million eur currencyadjusted sales previous year amounted million eur net sales region million eur change usa europecanadaaustralianew zealand eucan emerging markets japan animal health volume sales animal health business amounted million eur represents change previous year currencyadjusted net sales million eur change nexgard frontline heartgard ingelvac circoflex flexcombo sales figures negatively affected outbreak african swine fever asia tcm china taiwan hongkong region alone sales plunged swine vaccine ingelvac circoflex accordingly registered strong decline sales million eur increasing price pressure perceptible companys pets segment swine segment frontline antiparasitic achieved sales million eur lower previous year antiparasitics companys nexgard product performed strongly environment revenues drive growth million eur million eur growth yearoveryear heartgard another antiparasitic achieved growth registered sales million eur million eur group management report report economic position horse segment successful well realized currencyadjusted growth yearoveryear net sales region million eur change usa eucan alamea tcm asia latin america middle east africa china taiwan hongkong biopharmaceutical contract manufacturing biopharmaceutical contract manufacturing business maintained positive performance trend continued strong growth order situation entire business developed positively resulting high level capacity biopharmaceutical utilization biopharmaceutical production contract manufacturing sales discontinued operations sales mainly contain discontinued operations winding expected dis continued operations aggregate activities minor strategic importance boehringer ingelheim include amongst others obligations income resulting business swap sanofi particular service agreements well buscopan business brazil excluded sale financial position million eur financial funds cash flow operating activities cash flow investing activities cash flow financing activities change financial funds cash relevant transactions change financial funds due change consolidated companies exchange rate movements financial funds boehringer ingelheims financial management instruments methods aimed securing liquidity ensuring appropriate management financial risks financial activities therefore geared towards supporting business strategy laicnanif detadilosnoc stnemetats boehringer ingelheim annual report cash inflow operating activities amounted million eur represents increase million eur comparison previous year million eur attributable positive business trend cash flow investing activities amounted million eur similar level prior year million eur reflects significant investments external innovation strategic infrastructure support business activities high capital particular note rd investments amal therapeutics sa cooperations expenditure volume yuhan corporation soundtalks nv strengthen rd pipeline addition major invest ments fixed assets could reach milestones one investment made expan sion production facilities vienna biopharmaceutical contract manufacturing around million eur invested facility significant site group decades boehringer ingelheim made another major investment new development center bio pharmaceutical medicines bdc biberach bdc whose foundation stone laid intended create new jobs increase contract manufacturing capacity focuses therapeutic areas need treatment high cancer immunological diseases million eur invested bdc supplementing number significant investments boehringer ingelheims global biopharmaceutical development network important investment made animal health business nearly million eur invested new antigen production center regulatory animal disease control jonage france foundation stone major hightech facility laid fall planned overall investments production center million eur intended enable animal health business respond growing demand medicines treat footandmouth bluetongue disease cash outflow financing activities amount million eur comprises payments million eur charitable boehringer ingelheim foundation supports basic research fields natural life science payments parent companys shareholders mainly used pay personal taxes arising group business activities interest paid addition german private placement repaid overall taking consideration exchange effects changes within group consolidated companies led increase boehringer ingelheim groups financial funds million eur million eur group management report report economic position net assets position million eur change change assets intangible tangible assets financial assets fixed assets inventories trade accounts receivable receivables current assets cash cash equivalents current assets assets total assets equity liabilities group equity provisions pensions similar obligations tax provisions provisions accounts payable loans thereof residual term year liabilities liabilities difference capital consolidation total equity liabilities financial year boehringer ingelheims total assets amounted million eur increase million eur compared previous year million eur growth attributable particular increase volume financial funds cash longterm securi ties grew significantly due positive cash flow financial year longterm financial assets increased regard investment cash securities despite scheduled unscheduled depreciation amortization tangible intangible fixed assets increased due high volume capital expenditure strategic expansion companys business including human pharma research biopharmaceuticals vienna austria fremont california usa animal health france working capital receivables inventories especially picked result positive sales trend us increased inventories us france greece assets likewise increased thanks positive market trend plan assets pensions similar obligations us another reason increase higher deferred tax assets resulted temporary differences values consolidated companies tax balance sheets values consolidated balance sheet currency effects also resulted increases items asset side balance sheet laicnanif detadilosnoc stnemetats boehringer ingelheim annual report equity ratio increases group equity increased million eur due group profit well positive cur despite higher rency differences equity amounted million eur december equity ratio balance sheet total thus improved around december spite higher balance sheet total addition equity pension provisions longterm liabilities also available group long term total three items amounted million eur december representing share total assets consequently previous year longterm disposable capital covers intangible tangible fixed assets well working capital pension provisions increased germany particularly due lower actuarial discount rate increase provisions correlates change net sales since key elements represent provisions discounts usa decrease liabilities relates liabilities liabilities banks trade accounts payable mainly germany german private placement issued completely repaid liabilities declined mainly due release difference arising capital consolidation lower deferred tax liabilities temporary differences boehringer ingelheims positive performance financial year also reflected net assets position boehringer ingelheim remains profitable soundly financed company making considerable capital expenditure high rd expenditure ensure longterm growth thus independence group management report report opportunities risks report opportunities risks opportunities risk management assessing risks context holistic opportunities risk management also endeavor take account resulting opportunities opportunity management based strategies objectives company individual businesses operating business units integral part groupwide planning management systems responsible busi nesses functions bear direct responsibility early systematic identification analysis use opportunities boehringer ingelheim researchdriven innovative pharmaceutical company current research development activities naturally considered relevant opportu nity relevant projects already outlined research development rd chapter also look digitalization opportunity see new technological possibilities areas research particularly clinical development well support patients therapy aim risk management system implemented boehringer ingelheim identify businessspecific risks early possible particularly risks jeopardize continued existence company assess reduce reasonable level means suitable meas ures persons responsible key businesses functions also included process calculating assessing risks groupwide risk information system ensures identified risks analyzed assessed carefully following appropriate classification adequate risk manage ment measures initiated implementation consistently monitored year review internal auditing performed targeted routine audits well extraordinary audits around world addition adherence legal requirements internal group guidelines main focal points functionality systems effectiveness internal controls prevention loss assets efficiency structures processes corresponding adjustments optimizations initiated necessary individual risks important risks boehringer ingelheim exposed broken follow ing specific categories financial risks legal risks production environmental risks personnel risks industryspecific risks risks identified concrete appear controllable means specific management procedures term abstract used case risks completely controlled even means targeted management procedures regardless probability occurrence financial risks relevant financial risks broken follows currency risks credit country specific risks well financial investment shareholding risks currency risks global orientation business activities subject opportunities risks due exchange rate volatility particularly regard us dollar japanese yen group monitors quantifies risks regular intervals making predictable future business means relevant hedging strategies appropriate financial instruments forward exchange contracts resultant risks subsequently designated concrete controllable therefore limited laicnanif detadilosnoc stnemetats boehringer ingelheim annual report credit countryspecific risks boehringer ingelheim exposed various credit countryspecific risks result interna tional business activities portfolio trade accounts receivable trade accounts payable identified extraordinary risks group beyond usual level industry applies possible default risks receivables largely hedged economic political risks continue carefully track credit countryspecific risks posi tion respond negative changes timely manner risks consider moderate therefore regarded concrete financial investment shareholding risks group pursues defensive investment strategy management financial assets reflected orientation portfolio focused european economic monetary union emu government bonds top credit ratings shortterm money market deposits results concrete controllable thus limited risk therefore limited opportunities major part financial investments net book value strategic investments related companies affected market business circumstances leads higher level volatility fair market value specific risks covered respective impairments consolidated financial statements legal risks business activities group exposed legal risks distinction made regulatory liability patent protection risks regulatory risks boehringer ingelheim exposed risks arising legal disputes proceedings well official investigations legal administrative decisions ongoing future proceedings predicted regard resultant risks abstract high liability risks marketing sale pharmaceuticals exposed potential product liability risk boehringer ingelheim currently product liability insurance companys risk profile absolutely guarantee however insurance coverage maintained reasonable cost acceptable conditions sufficient protect boehringer ingelheim claim loss potential claims losses case foreseeable product liability insurance cover partially covers specific liability risk remaining risk exposure covered provision therefore see moderate risk group furthermore product liability claims could tie substantial financial resources management capacity detrimental companys image event market considers product unsafe ineffective result unexpected side effects see moderate abstract risk patent protection risks protection innovations trademark patent rights particular importance boehringer ingelheim research company commercial protective rights increasingly target attacks breaches taken necessary precautions allow us detect threats early stage commencing appropriate countermeasures defend legal position using legal means available us moderate risks regarded concrete group management report report opportunities risks production environmental risks quality management system compliance processes continuously optimized close coop eration relevant authorities order ensure compliance cgmp standards current good manufacturing practices risks area continue high significance group classified abstract order guarantee supply products market implemented measures guarantee reliable highquality supplies internal external customers addition supplier management procurement side also involves building internal standby capacities result see risk concrete risks areas environment health safety sustainability ehss preemptively mini mized ensuring global adherence high safety standards appropriate emergency plans drawn possible incidents kind practiced subjected comprehen sive quality testing regular intervals result measures risks classed concrete limited personnel risks boehringer ingelheim companies exposed demographic change resultant risk affected lack appropriately qualified personnel potential risk substantial impact companys business activities therefore included longterm planning process many years gained strategic significance result boehringer ingelheim counters risk means comprehensive personnel concept con text global personnel management also presents group opportunities regardless ethnic background gender religion offer companys employees development opportunities based professional abilities social skills personal aptitudes willingness take responsibility accordance needs company view countermeasures described risk regarded moderate concrete industryspecific risks boehringer ingelheim subject industryspecific business risks pharmaceutical industry risks partly materialized past financial year becoming increasingly important boehringer ingelheim due effects still considered high abstract addition loss exclusivity products established market risks associated develop ment registration new products risks increasingly include changing restrictive requirements relating pricing reimbursement many sales markets frequently prices pharmaceutical products subject state monitoring regulation also price pres sure cheaper generic drugs caused state reimbursement systems boehringer ingelheim therefore keeping close eye various changes sales markets takes appropriate meas ures response current developments overall statement risk situation current perspective aware risks alone conjunction risks could lead lasting impairment companys assets financial earnings position could jeopardize continued existence boehringer ingelheim laicnanif detadilosnoc stnemetats boehringer ingelheim annual report report expected developments boehringer ingelheim look back successful financial year made innova tions available patients previous year contributed significantly health livestock pets also achieved ambitious targets absolute numbers compar ison competitors creating foundation sustainable corporate development longterm growth look ahead optimistically work passionately continue improving human animal health however increasingly difficult market environment pharmaceutical industry combined volatility economic environment also makes planning capability increasingly challenging outbreak new coronavirus poses another multidimensional challenge chinese employees global production network global supply chain rapidly evolving environment take advantage opportunities present respond courageously risks materialize ensure continued success market view competitiveness remains important preserve make use financial flexibility growth innovation view many changes unfolding health care systems faced aging populations increasing price pressure many major markets especially exclusively core markets usa japan europe china expect limited growth impetus pharmaceutical industry coming year plan focus even strongly animal health customers solutions challenges well innovation product portfolio spread african swine fever countries remains risk priorities biopharmaceuticals busi ness supplying market products contract manufacturing customers beyond completion lscc largescale production facility vienna austria expect boehringer ingelheim achieve slight yearonyear increase net sales comparable basis adjusted currency extraordinary effects consistently high rd expenditure increased compatible strategic focus continuing drive growth flow new products achieved goal managing rd external innovation general partnerships continue pursue strategy invest external rd care close investigation therapeutic benefit associated prospects success flow innova tive medicines research pipeline shows short medium longterm growth potential group management report report expected developments addition patent expiry attacks patents major challenges facing researchdriven pharmaceutical industry increasing amount investment rd well bigger hurdles increased costs associated product approvals context increasing cost pressure health care systems outlined also particularly emphasized systems increasingly unwilling make substantial investments development new medicines contribute adequately increased efficiency system whole animal health research like wise requires major investments preventive research diagnostic options conjunction longer planning development cycles new products makes business less predictable requires us quickly recognize seize opportunities human pharma animal health one hand subjecting costs strategies continual monitoring adjustments end launched initiatives past years accelerate reaction changes reduce organizational complexities well lower cost base order create potential capital expenditure secure companys longterm success backdrop successful taking account expected economic market environment expect operating income comparable basis adjusted currency extraordinary effects level fiscal year familyowned company boehringer ingelheims primary aim remains creation value innovation supported longterm sustainable organic growth vision preserve companys independence competitiveness confident achieve ambitious targets thanks great innovative strength based comprehensive portfolio prospective products global presence support highly qualified motivated employees businesses remain committed ambition research develop inno vative products bring market areas medical need high break new ground therapeutic approaches human animal medicine aim endeavors make new medicines available humans animals treated effectively new therapies laicnanif detadilosnoc stnemetatspage c n l e f n n c l e e n overview selected consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements independent auditors report laicnanif detadilosnoc stnemetats boehringer ingelheim annual report overview selected consolidated companies ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aires italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia r japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium mexico usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein newport laboratories inc boehringer ingelheim brazil p r netherlands p r wilmington delaware biopharmaceuticals gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health brasil ltda paulo netherlands bv velserbroek boehringer ingelheim veterinary research center gmbh co kg hanover canada new zealand p r boehringer ingelheim middle east boehringer ingelheim animal health boehringer ingelheim animal health africa gmbh ingelheim rhein canada inc burlington new zealand limited auckland china p r philippines nanchang boehringer ingelheim boehringer ingelheim animal health animal health co ltd nanchang philippines inc makati city boehringer ingelheim animal health shanghai co ltd shanghai puerto rico p boehringer ingelheim animal health boehringer ingelheim animal health operations china co ltd taizhou puerto rico llc barceloneta boehringer ingelheim vetmedica china co ltd taizhou south africa denmark p boehringer ingelheim animal health south africa pty ltd randburg boehringer ingelheim animal health denmark copenhagen south korea france p r boehringer ingelheim animal health korea ltd seoul boehringer ingelheim animal health france lyon spain great britain p boehringer ingelheim animal health espaa sa barcelona boehringer ingelheim animal health uk limited bracknell distribution p production r research development consolidated financial statements overview selected consolidated companies ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina czech republic japan p r serbia boehringer ingelheim sa boehringer ingelheim spol sro nippon boehringer ingelheim co ltd boehringer ingelheim serbia doo buenos aires prague tokyo beograd belgrad boehringer ingelheim seiyaku australia denmark yamagata south africa boehringer ingelheim japan inc boehringer ingelheim pty ltd boehringer ingelheim danmark ingelheim pharmaceuticals tokyo north ryde copenhagen proprietary ltd randburg austria p r ecuador mexico p south korea boehringer ingelheim mexico sa de boehringer ingelheim rcv gmbh boehringer ingelheim del ecuador boehringer ingelheim korea ltd cv mexico city co kg vienna cia ltda quito seoul boehringer ingelheim vetmedica sa forschungsinstitut fr molekulare de cv guadalajara pathologie gesellschaft mbh vienna finland spain p boehringer ingelheim promeco sa viratherapeutics gmbh innsbruck boehringer ingelheim finland ky de cv mexico city boehringer ingelheim espaa sa espoo barcelona belgium netherlands scs boehringer ingelheim commv france sweden boehringer ingelheim bv alkmaar brussels boehringer ingelheim france sas boehringer ingelheim aktiebolag paris stockholm brazil p new zealand boehringer ingelheim brasl great britain boehringer ingelheim nz ltd switzerland r auckland qumica e farmaceutica ltda boehringer ingelheim ltd boehringer ingelheim schweiz paulo bracknell gmbh basel solana agro pecuria ltda arapongas norway amal therapeutics sa geneva greece p boehringer ingelheim norway ks canada boehringer ingelheim ellas ae asker taiwan b oh nr ti onger ingelheim canada ltd athens peru boehringer ingelheim taiwan ltd taipei hong kong boehringer ingelheim peru sac chile boehringer ingelheim hong kong lima thailand v b sao neh tir ai gn og e dr e n cg ill eheim ltda ltd hong kong philippines boehringer ingelheim thai ltd bangkok india boehringer ingelheim philippines china p boehringer ingelheim india private inc manila turkey pb ho aeh rmrin acg ee ur ti cg ae lslh ce oim l ts dh sn hgh aa ni g hai ltd mumbai poland boehringer ingelheim ila ticaret istanbul boehringer ingelheim indonesia p boehringer ingelheim sp z oo biopharmaceuticals china co ltd warsaw shanghai pt boehringer ingelheim indonesia usa p r boehringer ingelheim china jakarta portugal boehringer ingelheim investment co ltdshanghai pharmaceuticals inc boehringer ingelheim international israel unilfarmauniao internacional de wilmington delaware laboratrios farmacuticos lda trading shanghai co ltd boehringer ingelheim israel ltd lisbon boehringer ingelheim fremont inc shanghai tel aviv wilmington delaware boehringer ingelheim usa colombia italy p russian federation corporation wilmington delaware ooo boehringer ingelheim moscow boehringer ingelheim sa boehringer ingelheim italia spa vietnam santa f de bogot milan boehringer ingelheim animal health bidachem spa fornovo giovanni vietnam limited liability company ho chi minh city oiloftrop tcudorp boehringer ingelheim annual report consolidated balance sheet assets million eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets cash cash equivalents current assets prepaid expenses deferred tax assets exceeding amount plan assets total assets equity liabilities million eur notes shareholders capital group reserves balance sheet currency conversion difference equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions accounts payable loans liabilities deferred income deferred tax liabillities total equity liabilities explanations see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement consolidated profit loss statement million eur notes net sales changes finished goods work process work capitalized operating income total revenues cost materials personnel expenses amortization intangible assets depreciation tangible assets operating expenses operating income financial income holding income income taxes income taxes income taxes net income noncontrolling interests group profit explanations see relevant section notes consolidated financial statements due legal requirements shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report cash flow statement million eur income taxes including noncontrolling interests amortization reversal writedowns intangible assets depreciation reversal writedowns tangible assets change provisions pensions similar obligations including change plan assets change provisions noncash income expenses gain disposals consolidated companies gainloss disposals fixed assets grants received change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities interest income interest expenses income investments income taxes income taxes paid cash flow operating activities payments aquire intangible fixed assets payments aquire tangible fixed assets payments aquire financial fixed assets payments aquire generate plan assets payments relating purchase price adjustments disposed consolidated entities disposed fixed assets investments consolidated companies proceeds disposals intangible fixed assets proceeds disposals tangible fixed assets proceeds disposals financial fixed assets proceeds disposals consilidated entities interest received income dividends cash flow investing activities consolidated financial statements cash flow statement statement changes group equity cash flow statement million eur cash receipts grants interest paid cash payments shareholders parent company proceeds loans cash repayments loans cash flow financing activities change financial funds cash relevant transactions changes financial funds due change consolidated companies changes financial funds due exchange rate movements financial funds financial funds excl fixedasset investment securities cash cash equivalents investment securities within fixed assets source funds use funds statement changes group equity balance sheet equity attri currency butable non shareholders group conversion parent controlling million eur capital reserves difference company interests group equity balance contributions withdrawals net income changes consolidated companies currency effects balance withdrawals net income currency effects balance shareholders capital consists equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consists limited partners capital contribution shareholders personal taxes arising group business activities shown withdrawals group reserves oiloftrop tcudorp boehringer ingelheim annual report notes consolidated financial statements principles methods general principles consolidated financial statements boehringer ingelheim financial year prepared accord ance section german commercial code hgb line legal requirements prepare con solidated financial statements section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes equity consolidated financial statements prepared euros accordance section conjunction section hgb improve clarity transparency consolidated financial statements individual items consoli dated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes registry information parent company registered name ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company boehringer ingelheim group consists total subsidiaries germany abroad subsidiaries included consolidated financial statements ch boehringer sohn ag co kg full con solidation rules ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bears majority risks opportunities economic terms ch boehringer sohn ag co kg holds majority voting rights subsidiaries either directly indirectly accordance section hgb subsidiaries included consolidation reporting year individually collectively insignificant groups net assets financial earnings position total amount sales equity net income year subsidiaries included consolidation accounts less aggregated group financial statements totals two subsidiaries ongoing restrictions control due terms articles association companies also con solidated accordance section hgb consolidated financial statements notes total number subsidiaries decreased one compared previous year seven companies founded two companies acquired eight companies lost separate legal identity merger one affiliated company liquidated one company sold following subsidiaries exempted duty prepare disclosure annual financial statements management reports accordance section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim finanzierungs gmbh ingelheim rhein boehringer ingelheim rd beteiligungs gmbh ingelheim rhein boehringer ingelheim venture fund gmbh ingelheim rhein boehringer ingelheim invest gmbh ingelheim rhein boehringer ingelheim animal health france participations gmbh ingelheim rhein following subsidiaries exempted duty prepare disclose annual financial statements management reports accordance section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg hanover boehringer ingelheim participates one joint venture company included consolidated financial statements either using proportionate method equity method since material boehringer ingelheim holds interest fifteen associated companies accounted using equity method either due lack significance resulting effect groups total assets net income less oiloftrop tcudorp boehringer ingelheim annual report consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accordance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb acquisition method applied including subsidiaries consolidation first time accord ance section hgb companies included consolidation first time date company became subsidiary book value shares held parent company offset corresponding equity subsid iary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time consolidation remain ing positive balance recorded goodwill remaining negative balance recorded difference capital consolidation currency translation assets liabilities resulting foreign currency transactions translated using average spot exchange rate balance sheet date realization principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state side eurozone denominated foreign currency converted euros accordance section hgb using modified closing date rate method using modified closing date rate method asset liability items annual financial statements pre pared foreign currency translated euros using average spot exchange rate balance sheet date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation differences reported within consolidated equity reserves balance sheet currency conversion difference exchange rates groups important currencies changed follows reporting year basis eur spot rate average rate us dollar japanese yen chinese renminbi consolidated financial statements notes accounting policies fixed assets acquired tangible intangible assets carried cost less scheduled straightline amortization depreciation determined consideration technical economic circumstances based following useful lives goodwill years intangible assets years buildings years technical facilities machines years facilities operating equipment years straightline depreciation amortization used consolidated financial statements additional writedowns recorded reflect impairments value assets considered permanently impaired manufacturing costs include materials labor manufacturing costs appropriate portion materi als labor overheads depreciation fixed assets extent caused production manufacturing costs include financing costs capitalized intangible assets finite useful lives financial assets primarily include investment securities shareholder rights loans carried lower cost fair market value impaired event reasons impairment losses recognized previ ous financial years longer applicable corresponding reversals recorded current assets prepaid expenses deferred income exceeding amount plan assets inventories carried lower cost fair market value raw materials consumables supplies capitalized lower average acquisition prices fair market value balance sheet date finished goods work progress measured manufacturing cost basis individual calculations taking account directly attributable costs materials direct labor costs special direct costs appropriate share material production overhead costs productionrelated depreciation goods resale valued lower either acquisition cost fair market value oiloftrop tcudorp boehringer ingelheim annual report identifiable risks inventories arising aboveaverage storage periods diminished marketability lower replacement costs taken account recording appropriate valuation adjustments inventories valued lossfree deductions made expected sales prices reflect costs yet incurred receivables assets recognized cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted cash cash equivalents consisting cash balances banks checks recognized lower cost fair market value prepaid expenses recorded accordance section hgb include expenses paid advance respect defined period time balance sheet date deferred income recorded accordance section hgb include proceeds represent income relating defined period time balance sheet date fair market value pension plan assets corresponding present value pension obligations offset according german gaap exceeding amount plan assets capitalized separately difference capital consolidation difference capital consolidation reported december primarily result business swap boehringer ingelheims consumer healthcare business sanofis animal health business completed january resulted difference capital consolidation million eur difference amortized estimated period fifteen years remaining balance difference amounted million eur december difference capital consolidation reported december also included amount arising acquisition us company original difference amounted million eur difference amor tized estimated period ten years remaining balance difference amounted million eur december difference capital consolidation primarily influenced current year release million eur subsequent purchase price adjustments income release difference arising capital consolidation included operating income release made corresponding amortization assets acquired company identified purchase price allocation previously recognized compa nys balance sheet consolidated financial statements notes group reserves group reserves include retained earnings consolidated subsidiaries prior current years consolidation entries affect earnings provisions tax provisions provisions include uncertain liabilities expected losses executory contracts carried amount required settle obligation based reasonable prudent commercial judg ment including future cost price increases provisions remaining maturity one year discounted using matchedterm average market interest rate case pension provisions inter est rate results last ten years average market interest rate case provisions last seven years average market interest rate accordance rckstellungsabzinsungsverordnung german regulation discounting provisions accounts payable loans accounts payable loans recognized settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred income group financial statements carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reverse measured using tax rates specific respective consolidated company deferred tax balances discounted differences due consolidation measures accordance sections hgb also measured using companyspecific tax rates applicable time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without offsetting oiloftrop tcudorp boehringer ingelheim annual report notes consolidated balance sheet intangible assets acquired concessions advance million eur similar rights goodwill payments total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortization balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value consolidated financial statements notes tangible assets advance technical facilities payments land facilities operating construction million eur buildings machines equipment progress total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value oiloftrop tcudorp boehringer ingelheim annual report financial assets investments loans investments loans affiliated affiliated related related investment million eur companies companies companies companies securities loans total acquisition manufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders consolidated financial statements notes inventories million eur raw materials supplies unfinished goods finished goods goods resale advance payments suppliers accounts receivable assets residual term residual term million eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders million eur previous year around half million eur receivables affiliated companies almost exclusively consist receivables loans receivables related companies primarily consist trade accounts receivable provisions million eur pension provisions similar obligations tax provisions provisions oiloftrop tcudorp boehringer ingelheim annual report provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data germany example g mortality tables published prof dr klaus heubeck adjusted groupspecific death probabilities invalidity rates pension obligations significant countries calculated basis following actuarial parameters december germany usa japan discount rate salary increase pension increase discounting rates determined reference average market rates year maturities accordance german regulation discounting provisions march interest rates used discount sig nificant foreign pension obligations usa japan determined comparable parameters line german regulation discounting provisions march difference calculated accordance section hgb amounts million eur previous year million eur plan assets intended solely cover pension similar obligations unavailable creditors plan assets defined section sentence hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date million eur related amount pension obligations similar obligations million eur tax provisions tax provisions also include provisions double taxation risks resulted following implementation action plans organisation economic cooperation development oecd part interna tional initiative known action plan base erosion profit shifting beps consolidated financial statements notes provisions provisions mainly include provisions discounts guarantees personnelrelated provisions provisions outstanding invoices well provisions litigation legal claims compensation damages accounts payable loans residual term residual term less thereof less million eur year year years year bank loans accounts payable thereof trade accounts payable advance payments received accounts payable affiliated companies accounts payable related companies liabilities thereof taxes million eur social security liabilities million eur previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders million eur previous year million eur presented within liabilities item accounts payable affiliated companies include loans amounting million eur previous year million eur trade accounts payable amounting million eur previous year million eur oiloftrop tcudorp boehringer ingelheim annual report notes consolidated profit loss statement structure consolidated profit loss statement based total cost format taxes included operating expenses provide better view earnings position cost materials partially reclassified operating expenses previous years figure also adjusted million eur better comparability net sales businesses million eur human pharma animal health biopharmaceutical contract manufacturing sales discontinued operations region million eur americas europe asiaaustraliaafrica aaa operating income operating income includes income currency translation million eur previous year million eur cost materials million eur costs raw material supplies goods resale expenditure services consolidated financial statements notes personnel expenses million eur wages salaries social benefits retirement benefits thereof retirement benefits interest effects measurement provisions pensions similar obligations shown separate item financial income average headcount production marketing sales research development administration apprentices methodology used calculate average number employees revised consolidated finan cial statements calculated average originally based four previous endofquarter figures changed assessment based monthend figures figures adjusted line new methodology resulted overall difference employees amortization intangible assets depreciation tangible assets amortization intangible assets depreciation tangible assets include impairment losses mil lion eur previous year million eur operating expenses operating expenses include expenses currency translation million eur previous year million eur addition items included operating expenses mainly charges made record provisions legal risks restructuring well thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties oiloftrop tcudorp boehringer ingelheim annual report financial income million eur interest result provisions pensions similar obligations provisions interest expenses similar expenses interest expenses similar expenses amortization loss disposal financial fixed assets shortterm investments income investment securities longterm loans interest income similar income gains losses plan assets interest expense relating pension similar obligations offset accordance section sentence hgb total million eur earnings plan assets million eur interest expense relating pension similar obligations included interest result provi sions pensions similar obligations provisions holding income million eur writedowns financial assets writeups financial assets income related companies thereof disposal related companies income taxes million eur current income taxes deferred taxes current income taxes primarily include corporation trade tax expenses consolidated companies total balance deferred tax assets balance sheet date amounted million eur previous year million eur deferred tax assets primarily arise difference carrying amounts provisions pension obligations discounts tax goodwill intangible assets inventories tangible assets deferred tax liabilities million eur previous year million eur recorded primarily relate differences carrying amounts intangible assets tangible assets inventories provisions consolidated financial statements notes net income net income positively influenced nonperiod income primarily reversal provisions million eur previous year million eur negatively influenced nonperiod expenses mainly due taxes previous years million eur previous year million eur notes cash flow statement cash flow statement shows changes cash cash equivalents cash longterm investment securities sold time boehringer ingelheim group resulting cash inflows outflows reporting year accordance german accounting standard cash flow statement drs cash flow statement broken according cash flows operating activities cash flows invest ing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried spot rate effect exchange rate changes cash cash equivalents shown separately financial funds also include financial assets remaining maturity exceeding three months date acquisition financial assets converted cash shortterm financial funds december comprised following items million eur cash cash equivalents financial assets financial funds included million eur restricted funds balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosures contingent liabilities million eur liabilities guarantees warranties granting securities thirdparty liabilities risk utilization contingent liabilities assessed low account good net assets financial earnings position financial commitments offbalance sheet transactions million eur rental lease obligations residual financial commitments thereof pensionrelated obligations rental lease agreements million eur previous year million eur million eur previous year million eur relate longterm rental agreements nonconsoli dated subsidiaries purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease possible continue utilize properties fully indications time residual financial commitments include future capital expenditures million eur previous year million eur derivative financial instruments valuation units due extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging delivery goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organizational processes set internal guidelines strict separation trading processing documentation control consolidated financial statements notes risk positions regularly tracked analyzed measured special groupwide financial report positions entered periodically reevaluated monitored fair value derivative financial instruments calculated using generally accepted market valuation methods currency forwards based present value method taking account market data balance sheet date provisions million eur recognized currency forwards included hedge accounting negative fair value within one currency balance sheet date line imparity principle positive fair values within one currency recognized balance sheet date derivative financial instruments included hedge accounting valuation units follows nominal value fair value million eur foreign exchange forward contracts extent requirements hedge accounting foreign currency forward exchange contracts highly probable forecasted transactions accordance section hgb met foreign currency forward exchange contracts recognized balance sheet line net hedge presentation method following accounting policies apply recognition valuation units accordance section hgb economic hedges accounted financial statements use valuation units valuation units recognized foreign currency based net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales pur chases derived company planning expost analysis planning shown planned transactions highly probable opposing changes value hedged item hedging instrument fully offset critical terms maturity nominal amount foreign currency match effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges excess amounts hedging transactions included valuation units oiloftrop tcudorp boehringer ingelheim annual report december hedges highly probable forecasted net cash flows recognized follows january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy consolidated financial statements notes january february net cash flow million eur foreign exchange forward contracts million eur nominal value nominal value fair value usd usd usd jpy jpy jpy furthermore december valuation units foreign currency receivables recognized follows receivables million eur foreign exchange forward contracts million eur nominal value nominal value fair value rub rub rub pln pln pln amount hedged foreign currency risk correlates relative change exchange rate planning date realization date forecasted transactions currencies appreciate depreciate euro would foreign currency risk million eur without hedging research development expenses million eur research development expenses noncapitalized research development expenses include among items costs associated clinical studies total auditor fees total fees charged group auditor financial year amounted million eur million eur relates audits financial statements million eur assurance services million eur tax advisory services million eur services oiloftrop tcudorp boehringer ingelheim annual report subsequent events december asset purchase agreement signed hypera sa boehringer ingelheim sale buscopan business brazil agreement contains conditions closing execution asset sale including antitrust authority approval relevant conditions transaction expected concluded financial year amount equivalent approximately million eur bal ance sheet date agreed selling price since end financial year become aware events material signif icance group could lead reappraisal net assets financial earnings position shareholdings list companies included consolidated financial statements complete list shareholdings presented accordance section hgb included audited consolidated financial statements submitted german federal gazette ingelheim rhein march boehringer ag board managing directors hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer independent auditors report independent auditors report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statements audit opinion group manage ment report audited consolidated financial statements ch boehringer sohn ag co kg ingelheim rhein subsidiaries group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement changes group equity finan cial year january december notes consolidated financial statements including sum mary significant accounting policies addition audited group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtained audit except effects matter described section basis qualified audit opinion consoli dated financial statements audit opinion group management report accompanying consol idated financial statements comply material respects requirements german commercial law give true fair view assets liabilities financial position group december financial performance financial year january december accordance german legally required accounting principles accompanying group management report whole provides appropriate view groups position material respects group management report consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future devel opment pursuant section sentence hgb handelsgesetzbuch german commercial code declare except qualification audit opinion consolidated financial statements mentioned audit led reservations relating legal compliance consolidated financial statements group management report basis qualified opinion consolidated financial statements audit opinion group management report contrary section number letters b hgb total remuneration granted members former members board managing directors well pension provisions recognized recog nized former members board managing directors disclosed notes consolidated financial statements conducted audit consolidated financial statements group management report accord ance section hgb german generally accepted standards financial statement audits promul gated institut der wirtschaftsprfer institute public auditors germany idw responsibilities requirements principles described auditors responsibilities audit consolidated financial statements group management report section auditors report independent group entities accordance requirements german commercial professional law oiloftrop tcudorp boehringer ingelheim annual report fulfilled german professional responsibilities accordance requirements believe evidence obtained sufficient appropriate provide basis opinions consolidated financial statements group management report information management responsible information information comprises annual report exception audited consolidated financial statements group management report auditors report opinions consolidated financial statements group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider whether information materially inconsistent consolidated financial statements group management report knowledge obtained audit otherwise appears materially misstated responsibilities management consolidated financial statements group management report management responsible preparation consolidated financial statements comply material respects requirements german commercial law consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles addition management responsible internal control accordance german legally required accounting principles determined necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements management responsible assessing groups ability continue going concern also responsibility disclosing applicable matters related going concern addition responsible financial reporting based going concern basis accounting provided actual legal circumstances conflict therewith furthermore management responsible preparation group management report whole pro vides appropriate view groups position material respects consistent consolidated financial statements complies german legal requirements appropriately presents opportunities risks future development addition management responsible arrangements measures sys tems considered necessary enable preparation group management report accord ance applicable german legal requirements able provide sufficient appropriate evidence assertions group management report independent auditors report auditors responsibilities audit consolidated financial statements group manage ment report objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error whether group management report whole provides appropriate view groups position material respects consistent con solidated financial statements knowledge obtained audit complies german legal require ments appropriately presents opportunities risks future development well issue auditors report includes opinions consolidated financial statements group management report reasonable assurance high level assurance guarantee audit conducted accordance section hgb compliance german generally accepted standards financial statement audits promulgated institut der wirtschaftsprfer idw always detect material misstatement misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial state ments group management report exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements group management report whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinions risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal controls obtain understanding internal control relevant audit consolidated financial statements arrangements measures systems relevant audit group management report order design audit procedures appropriate circumstances purpose expressing opinion effectiveness systems evaluate appropriateness accounting policies used management reasonableness estimates made management related disclosures conclude appropriateness managements use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements group management report disclosures inadequate modify respective opinions conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease able continue going concern evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements present underlying transactions events manner consolidated financial statements give true fair view assets liabilities financial position financial performance group compliance german legally required accounting principles oiloftrop tcudorp boehringer ingelheim annual report obtain sufficient appropriate audit evidence regarding financial information entities business activ ities within group express opinions consolidated financial statements group manage ment report responsible direction supervision performance group audit remain solely responsible opinions evaluate consistency group management report consolidated financial statements conformity german law view groups position provides perform audit procedures prospective information presented management group management report basis sufficient appropriate audit evidence evaluate particular significant assump tions used management basis prospective information evaluate proper derivation prospective information assumptions express separate opinion prospective infor mation assumptions used basis substantial unavoidable risk future events differ materially prospective information communicate charged governance regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version signed kneisel krau wirtschaftsprfer wirtschaftsprfer german public auditor german public auditoroiloftrop tcudorp pages p r u c p r f l e l e c n human pharmaceuticals animal health boehringer ingelheim annual report respiratory diseases respiratory diseases common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma among bronchial asthma chronic inflammatory disorder prevalent chronic diseases frequent cause airways inflammation accompanied airway hyper morbidity premature deaths worldwide responsiveness leads narrowing airways recurrent episodes wheezing breathlessness coughing idiopathic pulmonary fibrosis ipf rare disease symptoms occur particularly night early severely debilitating ultimately lethal hours morning known asthma trig gered genetic environmental factors eg allergens copd viral infections unlike copd asthma occur early copd chronic disease lungs causes coughing childhood also present adolescents adults excessive mucus production dyspnea ultimately asthma often underestimated easytomanage condi destroys lung tissue alveoli thus gas exchange tion however almost one two patients asthma still affected leads limitation airflow causing experience symptoms receiving maintenance therapy shortness breath respiratory symptoms air putting increased risk potentially lifethreatening flow limitation partially reversible usually worsens asthma exacerbations addition patients often adjust time leading disability ultimately death symp daily lives accommodate conditions avoid physical toms excess cough breathlessness main exertion daytoday activities negative impact reasons copd stressful patients lung emphy quality life sema chronic bronchitis main manifestations copd copd caused continuous damage lungs resulting inhaling pollutants primarily cigarette smoke however factors also need considered including indoor outdoor air pollution course copd disease occurs second half humans life character ized accelerated loss lung function compared mal ageing occasional sudden worsening symptoms function referred acute exacerbations lead downward spiral worsening symptoms thus inactivity product portfolio human pharmaceuticals indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients copd pulmonary disease copd spiriva handihaler including chronic bronchitis emphysema spiriva respimat maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance bronchodilator treat ment patients aged six years older severe asthma experienced one severe asthma exacerbations past year spiriva respimat approved use asthma eu japan usa many countries label varies country please refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow obstruction pulmonary disease copd stiolto respimat olodaterol hydrochloride patients chronic obstructive pulmonary inspiolto respimat disease copd c hronic obstructive striverdi respimat olodaterol hydrochloride maintenance treatment patients chronic pulmonary disease copd obstructive pulmonary disease copd reversible bronchospasms combivent respimat ipratropium bromide combination shortacting anticholinergic associated obstructive salbutamol sulphate betaadrenergic management airway diseases reversible bronchospasms associated obstructive airway diseases patients requir ing one bronchodilator c hronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic obstructive chronic bronchitis pulmonary disease copd mild moder bronchial asthma ate bronchial asthma adulthood child hood supplement betaagonists cases acute asthma c hronic obstructive airway berodual ipratropium bromide prevention treatment symptoms disorders bronchodual fenoterol hydrobromide chronic obstructive airway disorders duovent reversible airflow limitation bronchial asthma especially chronic bronchitis without emphysema boehringer ingelheim annual report respiratory diseases continued idiopathic pulmonary fibrosis ipf systemic sclerosis associated interstitial lung ipf chronic progressive lung disease associated disease sscild markedly reduced life span affecting many systemic sclerosis ssc also known scleroderma rare people per worldwide ipf characterized progres incurable autoimmune disease affecting connective tissue sive scarring lung tissue loss lung function disease estimated affect people every time development scarred tissue called fibrosis europe million worldwide ssc impacts four times time tissue thickens stiffens scarring lungs many women men onset disease typically lose ability take transfer oxygen blood occurs young age years cause stream vital organs get enough oxygen result scarring fibrosis skin well major organs individuals ipf experience shortness breath even heart lungs digestive tract kidneys resting often difficulty coping demands lifethreatening complications approximately patients everyday life due limited physical capacity develop significant pulmonary involvement within three years diagnosis ssc affects lungs cause intersti acute ipf exacerbations defined rapid deteriorations tial lung disease ild known sscild key driver symptoms lung function within days weeks mortality among people ssc accounting approxi events occur point course disease even mately one third deaths first presentation associated high mortality patients ipf risk acute ipf exacerbations product portfolio human pharmaceuticals indications brand names active ingredients bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks prophylaxis exerciseinduced asthma bron chiale symptomatic treatment allergic non allergic asthma bronchiale conditions reversible airway narrowing eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patients bron allergic rhinitis flurinol chial asthma prophylaxis symptomatic treatment allergic rhinitis diopathic pulmonary fibrosis ofev nintedanib treatment patients idiopathic pulmo ipf nary fibrosis ipf ystemic sclerosis associated approved usa brazil canada japan interstitial lung disease countries therapy sscild slow sscild rate decline pulmonary function boehringer ingelheim annual report cardiovascular metabolic diseases cardiovascular cv disease leading cause death prevention treatment venous worldwide still increasing prevalence currently thromboembolism responsible nearly one three deaths worldwide one key venous thromboembolism vte umbrella term risk factor developing cardiovascular disease pres encompasses deep vein thrombosis dvt pulmonary ence diabetes people type diabetes two four embolism pe dvt occurs thrombus blood clot forms times likely develop cardiovascular disease peo deep vein commonly leg partially com ple without diabetes result life expectancy pletely blocks flow blood thrombus grows por years shorter proper control diabetes treat tion may break away main clot travel circu able risk factors therefore vital prevention cardio latory system lungs lodging blood clot vascular events arteries lung called pe vte serious disorder potentially fatal consequences stroke stroke rapidly developing loss brain functions caused patients undergoing orthopedic surgery considerable disrupted blood flow affected brain tissue risk developing dvt chronic venous insufficiency due ischemia lack blood supply caused thrombo pulmonary hypertension may develop longer term sis embolism due bleeding hemorrhagic stroke prevent vte events consequences orthopedic result affected area brain unable function surgery patients receive kind thromboprophy damage quickly becomes permanent untreated stroke laxis patients already suffered vte require anti acute event requiring emergency diagnosis interven coagulant treatment secondary prevention recurrent tion worldwide stroke one leading causes death thromboembolic event longterm disability reversing anticoagulation symptoms transient ischemic attack tia similar anticoagulation therapy offers important benefits patients stroke last minutes hours risk thromboembolic events however even though rare result permanent neurological damage tia may pre may situations rapid reversal anticoagulation cede stroke emergency medical care subsequent pre medically necessary eg patient taking anticoagulant ventive treatment may necessary involved severe car accident needs emergency surgery atrial fibrillation atrial fibrillation af common sustained heart rhythm condition affecting approximately total pop ulation one four adults develops af lifetime patients af higher risk developing blood clots upper left heart chamber cause stroke clot breaks loose travels brain af leads fivefold increase risk stroke resulting three million patients worldwide suffering afrelated strokes year patients af risk stroke reduced appropri ate anticoagulation therapy product portfolio human pharmaceuticals indications brand names active ingredients stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients atrial fibrillation primary prevention venous prazaxa primary prevention venous thromboembolic thromboembolic events events vte adults elective total hip orthopedic surgery knee replacement surgery treatment secondary prevention venous treatment deep vein thrombosis dvt thromboembolic events pulmonary embolism pe secondary prevention recurrent dvt pe adults pecific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicated adult patients treated pradaxa dabigatran etexilate rapid reversal anticoagulant effects required emergency surgeryurgent procedures lifethreatening uncontrolled bleeding hypertension micardis telmisartan treatment hypertension reduction c ardiovascular morbidity risk myocardial infarction heart attack mortality prevention stroke death cardiovascular cv causes patients years age older high risk developing major cv events unable take ace inhibitors us reduction cardiovascular morbidity patients manifest atherothrombotic car diovascular disease history coronary heart disease stroke peripheral arterial disease patients type diabetes mellitus documented target organ damage eu hypertension micardisplus telmisartan treatment hypertension alone micardis plus hydrochlorothiazide antihypertensive agents lower blood pres micardis hct sure lowering blood pressure reduces risk comicardis fatal nonfatal cardiovascular events primarily strokes myocardial infarctions indicated initial therapy us treatment essential hypertension micardisplus fixed dose combination indicated adults whose blood pressure adequately controlled telmisartan alone eu boehringer ingelheim annual report cardiovascular metabolic diseases continued hypertension cardiovascular diseases hypertension high blood pressure chronic disease blood pressure chronically elevated hypertension also one major risk factors stroke heart attacks heart failure chronic renal failure primary goal anti hypertensive treatment prevent cardiovascular events reduce risk cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack occurs thrombus blood clot suddenly prevents blood flow area heart muscle unless blood flow restored quickly affected section heart muscle becomes permanently damaged heart attacks one common causes death industrialized countries product portfolio human pharmaceuticals indications brand names active ingredients hypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial therapy micardis amlo patients likely need multiple antihypertensive micardis duo agents achieve blood pressure goals us addon therapy adult patients ade quately controlled blood pressure amlodip ine replacement therapy adult patients receiving telmisartan amlodipine separate tablets eu acute ischemic stroke actilyse alteplase fibrinolytic treatment acute ischemic stroke acute myocardial infarction actilyse cathflo acute myocardial infarction acute massive cute massive pulmonary pulmonary embolism fibrinolytic treatment embolism occluded catheters c atheter clearance due thrombotic occlusion econdary prevention aggrenox dipyridamole prevention stroke following initial first stroke transient ischemic asasantin acetylsalicylic acid stroke transient ischemic attacks tia attacks tia asasantin retard acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction hypertension catapresan clonidine treatment hypertension catapres clonidine hydrochloride catapressan boehringer ingelheim annual report cardiovascular metabolic diseases continued diabetes addition cardiovascular disease serious complications type diabetes chronic progressive condition associated diabetes include elevated blood sugar levels cause longterm complications treated estimated four million deaths nephropathy culminating renal failure requiring dialysis worldwide every year linked directly longterm retinopathy potential loss vision effects diabetes type diabetes common form peripheral neuropathy risk developing foot ulcers disease accounts cases potentially requiring foot leg amputations developed world currently million people autonomic neuropathy cause gastrointestinal world live diabetes represents enormous genitourinary cardiovascular symptoms sexual dys burden health care systems globally without effective pre function vention management strategies estimated number cases reach million addition type diabetes one major risk factors cardiovascular disease life expectancy people type diabetes high cardiovascular risk decreases average years overall around half deaths people type diabetes caused concomitant cardiovascular dis ease indicating high unmet medical need product portfolio human pharmaceuticals indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment adults type diabetes tradjenta mellitus adjunct diet exercise trazenta improve glycemic control used monotherapy trayenta metformin tolerated contraindi cated combination therapy type diabetes mellitus jentadueto linagliptin metformin treatment adults type diabetes trayenta duo hydrochloride mellitus adjunct diet exercise trajenta duo improve glycemic control treatment trajentamet metformin lead sufficient control patients treated trajenta linagliptin metformin type diabetes mellitus jardiance empagliflozin treatment adults type diabetes melli jardianz tus adjunct diet exercise improve glycemic control reduce risk cardiovascular death adults type diabetes mellitus established cardiovascu lar disease us indication december label varies country please refer local product information type diabetes mellitus synjardy empagliflozin treatment adults type diabetes melli jardiance duo metformin tus adjunct diet exercise improve hydrochloride glycemic control treatment empagliflozin metformin appropriate us indication december label varies country please refer local product information type diabetes mellitus glyxambi empagliflozin linagliptin treatment adults type diabetes melli tus adjunct diet exercise improve glycemic control adults type diabetes mellitus empagliflozin linagliptin appropriate treatments us indication march label varies country please refer local product information diabetes portfolio collaboration eli lilly company boehringer ingelheim annual report oncology cancer threat global health estimated different subtypes small cell lung cancer million new cases cancer diagnosed worldwide sclc nonsmall cell lung cancer nsclc ten million people died cancer nearly one six global different molecular genetic aberrations mutations present deaths world cancer factsheet com tumor identified focusing molecular mon diagnosed cancer types lung cancer nearly changes specific respective subtype lung breast cancer nearly colorectal cancer prostate cancer targeted therapies become effective cancer stomach cancer treatments show survival benefit time less harmful normal cells thereby reducing side lung cancer effects lung cancer refers malignant abnormal cell growth inside lung tissue common cancer esti mated million new cases per year worldwide smok ing primary cause disease contributing almost cases recently however incidence lung cancer among nonsmokers increased lung cancer poor prognosis million deaths per year representing nearly cancer deaths lung cancer symptoms unspecific disease may take many years appear late diagnosis advanced stage disease results often dismal prognosis lung cancer patients surviving five years following diagnosis product portfolio human pharmaceuticals indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib firstline treatment adult patients locally nsclc gilotrif advanced metastatic nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations treatment patients locally advanced metastatic nsclc squamous histology progressing platinumbased chemotherapy n onsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally recurrent nonsmall cell lung cancer nsclc adenocarcinoma tumor histology firstline chemotherapy boehringer ingelheim annual report diseases central nervous system mental neurological diseases depression associated pd depression sleep disorders parkinsons disease significantly impact patients primary symptoms result lack neuro families also substantial burden society transmitter dopamine distinct areas human brain parkinsons disease restless legs syndrome rls parkinsons disease pd degenerative disorder cen restless legs syndrome rls common neurological disor tral nervous system patients usually notice motor symptoms der characterized uncontrollable urge move legs like hand shaking tremor first sign disease primarily occurring evening night hours usually may progress include shaking arms legs accompanied unpleasant sometimes painful sensa head motor symptoms may develop time tions legs well disturbed sleep resulting daytime include stiffness often results loss facial expression tiredness sleepiness sensations felt deep within gradual slowing loss motion freezing legs described creeping crawling aching patients also suffer nonmotor symptoms infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symp toms infections resulting damage human immune system caused human immunodeficiency virus hiv untreated infection hiv progressively reduces effectiveness immune system leaves individuals sus ceptible opportunistic infections tumors babies infected mothers risk getting virus preg nancy childbirth breastfeeding product portfolio human pharmaceuticals indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mono mirapexin therapy combination levodopa pexola symptomatic treatment idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders initiating maintaining sleep insomnia requiring pharmacological inter vention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv infection viramune xr several countries prevention mothertochild transmission hiv preg nant women taking antiretroviral therapy time labor prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treat ment hivinfected patients coadminis tered mg ritonavir treat mentexperienced infected hiv strains resistant one protease inhibitor boehringer ingelheim annual report livestock swine infectious respiratory diseases infectious enteric diseases ingelvac circoflex first singledose piglet vaccine enterisol ileitis first oral live vaccine control porcine circovirus disease pcvd vaccine ileitis globally prevalent enteric disease swine provides significant reduction mortality acute phase caused lawsonia intracellularis licensed improve pcvd well improved growth rates chronic phase weight gain reduce growth variability associated disease ingelvac circoflex protects minimal disease enterisol ileitis helps reduce total anti systemic adverse reactions injection site swellings microbial use pork production used gestation lactation ingelvac prrs products licensed active immunization respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provides proven safety efficacy rapid onset longlasting immunity mycoplasma hyo pneumoniae hyo single dose ingelvac mycoflex contains impranflex adjuvant allows fresh mixing ingelvac circoflex form flexcombo ingelvac provenza protects multiple iavs strains decreases nasal shedding providing protection pigs vulnerable product portfolio animal health indications brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunization pigs diseases porcine circovirus age two weeks porcine circovirus type pcv type reduce mortality clinical signs including weight loss lesions lymphoid tissues associated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viremia infectious respiratory ingelvac prrs mlv attenuated live vaccine depending product active diseases ingelvac prrsflex eu prrs virus type type immunization pigs various ages reprocyc prrs eu porcine reproductive respiratory syndrome virus prrs infectious respiratory ingelvac mycoflex inactivated vaccine active immunization pigs diseases mycoplasma age three weeks reduce lung lesions hyopneumoniae following infections mycoplasma hyo pneumoniae infectious respiratory ingelvac provenza attenuated live influenza vaccine vaccination pigs one day age diseases laiv older influenza virus strains hn hn infectious enteric diseases enterisol ileitis attenuated live vaccine active immunization pigs lawsonia intracellularis age three weeks intestinal lesions caused lawsonia intracellularis infection reduce growth variability loss weight gain associated disease boehringer ingelheim annual report livestock cattleruminants cattleruminants business global leader antiparasitic brands ivomec longrange eprinex world renowned parasiticides treat protect grazing animals harmful effects internal external parasites zactran treats cattle bacterial pneumonia sheep digital dermatitis infections bovela active immunization cattle three months age terms reproductive infectious diseases product portfolio animal health indications brand names active ingredients internal external ivomec ivermectin depending formulation product parasites cattle treatment nematodes lice mites ticks flies lungworms liver flukes nternal external longrange eprinomectin longacting theraphase technology used develop parasites cattle formulation eprinomectin allows single treatment last days long enough break parasite life cycle effectively reduce parasite burdens pasture longrange effective con trol internal external parasites cattle gastrointestinal roundworms lung worms grubs mites nternal external eprinex eprinomectin depending formulation product parasites ruminants treatment nematodes lice mites ticks flies lungworms cattle sheep bacterial causes respiratory zactran gamithromycin depending species indication country disease interdigital registration product treat dermatitis footrot ment metaphylaxis control respiratory disease cattle caused key bacteria mannheimia pasteurella histophilus mycoplasma footrot disease sheep caused key bacteria fusobacterium dichelobacter reproductive infectious bovela bovine viral diarrhoea bvd reduces hyperthermia minimizes diseases cattle types reduction leukocyte count caused bovine viral diarrhoea virus bvdv bvdv reduces virus shedding viremia caused bvdv prevents birth persistently infected calves caused transplacental infection boehringer ingelheim annual report livestock cattleruminants continued vaccine pyramidpresponse part expanding portfolio respiratory reproductive vaccines prevent diseases affect livestock metacam nonsteroidal antiinflammatory drug nsaid helping minimize losses inflammation tissue damage animals suffering disease hence addressing need maintained profitability concern farm animal wellbeing product portfolio animal health indications brand names active ingredients infectious respiratory pyramid family multivalent vaccine combina pyramidpresponse family vaccines diseases reproductive presponse tions including different modified live provides broad coverage bvd types disorders cattle viruses bovine viral diarrhoea bvd ibr brsv pi mannheimia haemolytica types infectious bovine rhino single dose contain tracheitis ibr parainfluenza pi metastim adjuvant system enhance bovine respiratory syncytial virus animals response greater protection brsv bacteria pasteurella us canada multocida mannheimia haemolytica metastim registered trademark l canicola l grippotyphosa l hardjo zoetis services llc l icterohaemmorrhagiae l pomona pain inflammatory metacam meloxicam treatment mastitis lactating cows disorders control pain associated dehorning surgery also indicated use calves affected diarrhoea cattle suffering respiratory disease boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consists significant range live inactivated vaccines broilers layers breeder hens providing protection critical viral bacterial diseases like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syn drome avian coryza portfolio preventive products helps producers worldwide provide safe affordable abun dant sustainable highquality poultry meat eggs product portfolio animal health indications brand names active ingredients various viral bacterial gallimune polyvalent attenuated live inacti vaccination healthy chickens diseases poultry gallivac vated vaccine containing antigens diseases caused included antigens volvac vaccination avian influenza prevention common diseases newcastle disease avian broiler chickens diseases responsible coryza egg drop syndrome losses egg production layers infectious bronchitis infectious bursal disease gallibacterium anatis infectious bursal disease vaxxitekhvt ibd serotype live mareks disease vector prevent mortality reduce clinical mareks disease live vhvt recombinant virus signs lesions infectious bursal disease diluent onset protection two weeks protection extends nine weeks reduce mortality clinical signs lesions mareks disease onset protection four days single vaccination sufficient provide reliable protection risk period infectious bursal newcastle vaxxitek hvt ibd ndbursal disease mareks disease new vaccination dayold embryos mareks diseases castle disease vaccine serotype onedayold chickens effective live mareks disease vector vaccine standard variant infectious bursal new contains gene ibd ndv castle mareks disease diluent newcastle disease nd avinew live newcastle disease virus broiler chickens one day age active vggaavinew strain immunization newcastle disease reduce mortality clinical signs associated disease future layer future breeder pullets age four weeks priming active immunization egg drop caused newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lay mareks disease prevexxiontm rn live herpes virus chimera vaccine recommended ovo serotype strain rn vaccination dayold embryonated diluent chicken eggs protect virulent mareks disease newcastle mareks newxxitektm hvt nd live mareks disease vectored vaccination dayold embryos diseases virus serotype onedayold chickens effective contains gene insert mareks disease newcastle disease newcastle disease diluent boehringer ingelheim annual report veterinary public health vph work governments private partners toward rabisin inactivated vaccine rabies available improving control eradicating diseases footand clear colorless suspension injection mouth disease bluetongue virus rabies btv pur multistrain vaccine used active immunization footandmouth vaccines portfolio works active sheep cattle prevent viremia reduce clinical immunization cattle sheep pigs reduce clinical signs signs caused bluetongue virus mortality following exposure footandmouth disease fmd virus product portfolio animal health indications brand names active ingredients footandmouth disease aftopor mix inactivated fmd virus antigens fmd vaccines highly potent purified fmd aftovaxpur widest range vaccine antigens aftopor aftovaxpur aftobov aftovax strains oleosa potential marker properties aftobov oleosa allow differentiation infected aftovaxpur doe vaccinated animals diva endemic emergency situations aftovaxpur doe suitable emergency situations rabies rabisin rabisin inactivated adjuvanted rabisin used active immunization raboral vrg rabies glycoproteins raboral vrg dogs cats reduce mortality clini vaccinavectored rabies vaccine cal signs due rabies infection immunity demonstrated one month vaccina tion shown persist next revaccination dose raboral vrg oral rabies recombinant vaccine protects raccoons coyotes rabies thereby reducing risk exposure rabies humans domestic animals sold government agen cies conducting rabies control programs bluetongue btv pur mix inactivated bluetongue virus active immunization sheep prevent viremia reduce clinical signs caused bluetongue virus serotypes andor combination maximum serotypes active immunization cattle prevent viremia caused bluetongue virus serotypes andor reduce clinical signs caused bluetongue virus serotypes andor combination maximum serotypes onset immunity demonstrated three weeks five weeks sheep btv primary vaccination course btv btv cattle btv btv serotypes boehringer ingelheim annual report companion animals horse main equine products focus prevention treat eqvalanzimecterin contains ivermectin leading ingredi ment parasite infestations management solutions ent controls wide variety important internal parasites chronic diseases gastric ulcers vaccines equine port including bots benzimidazoleresistant small strongyles folio also includes range flagship products treat easytoadminister oral paste eqvalanzimecterin ment joint disease colic respiratory disease well approved adult horses foals young six weeks line nutraceuticals age prascend indicated treatment pituitary pars eqvalan duogold zimecterin gold combines ivermectin intermedia dysfunction ppid also known equine praziquantel ingredient specifically controls tape cushings disease clinical signs ppid hypertrichiosis worms laminitis change body conformation lack perfor mance treatment prascend lifelong articell forte worlds first licensed veterinary stem cell product readytouse intraarticular injection vetera vaccines first us vaccine portfolio include chondrogenic induced mesenchymal cells treatment multiple convenient combinations disease protection lameness horses articell forte one latest addi horses young four months age vaccines pro tions equine portfolio available range tect many nine infectious organisms including countries within eu influenza herpes west nile virus tetanus others enables customised protection horse limited aservo equihaler first inhalation product needle injections treatment severe equine asthma product novel glucocorticoid prodrug ciclesonide inhalation solution gastrogardulcergard indicated treatment delivered inhaler specifically designed use horses prevention equine gastric ulcers one implementing soft mist technology derived common diseases horses gastrogard supplied respimat inhalers human pharma exciting new intro easytouse oral paste form first choice duction gained final authorization product availability treatment gastric ulcers since launch ulcergard eu early approvals countries usa preventive choice horses expected due course increased risk developing gastric ulcers product portfolio animal health indications brand names active ingredients pituitary pars intermedia prascend pergolide mesylate symptomatic treatment clinical signs dysfunction ppid associated pituitary pars intermedia dysfunction ppid also known equine cushings disease combination vaccine vetera eastern western venezuelan vaccination healthy horses aid nine common diseases encephalomyelitis tetanus west nile prevention diseases caused horses virus equine herpes virus equine included antigens us canada influenza viruses equine gastric ulcers gastrogard omeprazole treatment prevention gastric ulcers ulcergard prevention recurrence gastric ulcers horses foals four weeks age older internal parasites eqvalan ivermectin treatment prevention parasitic zimecterin ivermectin praziquantel infestations horses donkeys due eqvalan gold large small strongyles ascarids eqvalan duo goldduo includes treatment zimecterin gold tapeworms reduction mild articell forte chondrogenic induced equine treatment mild moderate lameness moderate recurrent lameness allogeneic peripheral bloodderived linked noninfective joint inflammation associated nonseptic mesenchymal stem cells horses contains stem cells joint inflammation horses obtained equine blood stem cells develop types cells stem cells active substance mesenchymal stem cells treated develop cartilage cells severe equine asthma aservo equihaler ciclesonide inhalation solution alleviation clinical symptoms severe equine asthma characterized coughing nasal discharge nasal flaring increased breathing effort rest abnormal lung sounds articell forte registered trademark global stem cell technology boehringer ingelheim annual report companion animals pets pets portfolio offers diverse solutions heartgard plus contains active ingredients ivermectin important needs canine feline health including indus pyrantel soft beef chew given monthly tryleading parasiticides vaccines therapeutics address ivermectin effective preventing deadly heartworm dis major chronic diseases heart failure kidney diseases hyperten ease pyrantel effective treatment control round sion epilepsy osteoarthritis worms well hookworms heartgard launched first monthly heartworm preventative still years frontline leader flea tick bestselling heartworm preventative world control dogs cats one trusted brands animal health frontline continues bring innovation broadline offers pet owners allinone convenience providing category recent launch frontline triact confidence cat broadest possible protection features repellency insecticidal efficacy many protects cats broadest spectrum internal disease carrying flying insects decreases risk external parasites including adult fleas flea eggs flea larvae transmission vectorborne pathogen ticks heartworms hookworms roundworms tapeworms nexgard contains active ingredient afoxolaner first new class heart treatments termed inodilators first oral medication treats fleas ticks dogs vetmedin shown significantly improve clinical efficacy palatable beefflavored soft chew signs extend life expectancy dogs congestive heart formulation nexgard currently bestselling pet medica failure originating dilated cardiomyopathy valvular tion animal health industry insufficiency mitral andor tricuspid regurgitation recent studies also shown used preclinically appro nexgard spectra combines flea tick efficacy priate asymptomatic cases either dilated cardiomyopathy afoxolaner nexgard broadspectrum deworming doberman pinschers valvular insufficiency vetmedin sig ingredient milbemycin oxime beefflavored chew nificantly delays onset clinical signs congestive heart nexgard spectra effective treating fleas failure ticks also protects dogs deadly parasites heartworm lungworm well gastrointestinal parasites data file novel combination fipronil permethrin frontline triactfrontect reduces risk transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus ticks dogs jongejan et al parasites vectors data file data file product portfolio animal health indications brand names active ingredients antiparasitic caninefeline frontline fipronil frontline indicated treatment external parasites frontline combo fipronilsmethoprene prevention fleas ticks chewing lice frontline plus fipronilpermethrin dogs cats aids control frontline triact sarcoptic mange dogs frontect frontline plus frontline combo indicated treatment prevention fleas ticks chewing lice dogs cats also breaks flea life cycle preventing development immature stages aids control sarcoptic mange dogs frontline triactfrontect indicated treatment prevention flea tick infestations repellent antifeeding activity necessary sandflies biting flies andor mosquitos dogs antiparasitic canine external nexgard afoxolaner nexgard delivered highly palatable parasites beefflavored chew kills adult fleas indicated treatment prevention flea infestations treatment control tick infestations dogs puppies one month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra delivered highly external parasites milbemycin oxime palatable beefflavored chew kills adult fleas indicated treatment prevention flea tick infestations pre vents heartworm disease treats con trols hookworm roundworm whipworm lungworm infestations dogs puppies antiparasitic canine internal heartgard plus ivermectin use dogs prevent canine heartworm parasites pyrantel disease eliminating tissue stage heartworm larvae month days infection treatment control roundworms hookworms antiparasitic feline internal broadline fipronil smethoprene protects cats broadest spectrum external parasites eprinomectin praziquantel internal external parasites including adult fleas flea eggs flea larvae ticks heartworms hookworms roundworms tapeworms congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilated cardiomyopathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilated cardiomyopathy preclinical stage asymptomatic increase left ventricular endsystolic enddiastolic diameter doberman pin schers treatment dogs myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increased heart size delay onset clinical symptoms heart failure boehringer ingelheim annual report companion animals pets continued metacam nonsteroidal antiinflammatory drug nsaid semintra firstever licensed angiotensin receptor available oral suspension tablets injectable blocker arb veterinary use provides proven conve solution dogs oral suspension injectable nient safe compliance solution cats cat owners solution cats dogs indications include allevia vets semintra available mgml mgml oral solu tion inflammation pain acute chronic mus tion semintra mgml first launched culoskeletal disorders well reduction pain follow reduction proteinuria associated chronic kidney dis ing surgery cats indications include alleviation ease ckd cats semintra mgml inflammation pain acute chronic musculoskeletal launched control ustreatment eu feline systemic disorders well alleviation mild moderate hypertension first vetlicensed product feline postoperative pain variety formulations offers veteri hypertension us narians owners flexibility use formulation prefer individual cases manage various levels since launch prozinc become proven inflammation pain associated licensed indica choice feline patients owners convenient man tions agement feline diabetes reliable longacting insulin treatment option made difference previcox launched new nsaid selective lives cats owners approval prozinc cox inhibitor dogs addresses one categorys canine patients opportunity expand main drivers need efficacious pain relief ensured impact become firstchoice solution successful man safety long term previcox indicated relief agement diabetes dogs cats pain inflammation associated osteoarthritis relief postoperative pain inflammation associ pet vaccine product portfolio includes purevax feline ated soft tissue orthopedic dental surgery vaccines formulated provide effective protection without use adjuvants recombitek providing targeted protec tion dogs recombinant technology product portfolio animal health indications brand names active ingredients pain inflammatory metacam meloxicam metacam used reduce specific types diseases postoperative pain inflammation well musculoskeletal disorders dogs cats pain inflammatory previcox firocoxib relief pain inflammation associ diseases ated osteoarthritis well specific types postoperative pain dogs chronic kidney disease ckd semintra telmisartan management chronic kidney disease ckd cats feline systemic hypertension us eu cats hypertension cats diabetes prozinc protamine zinc treatment diabetes mellitus cats dogs achieve reduction hyper glycemia improvement associated clinical signs feline vaccines portfolio purevax feline herpes virus purevax fully adjuvantfree feline feline calicivirus vaccine range leverages innovative feline panleukopenia virus canarypox technology felv rabies chlamydophila felis also offers sustained protection rabies recombinant vectored feline three years leukemia virus recombinant vectored rabies virus canine vaccines portfolio recombitek recombinant vectored canine recombitek features complete line distemper virus canine vaccines including canine parvovirus recombitek lyme vaccine canine adenovirus type contains ospa nonadjuvant formulation canine parainfluenza virus coronavirus rekombitek oral bordatella effective leptospira canicola safe protection made easy leptospira grippotyphosa leptospira icterohaemorrhagiae leptospira pomona recombinant borrelia burgdorferi bordetella bronchiseptica us othersboehringer ingelheim annual report ch boehringer sohn ag co kg ingelheim rhein comparison balance sheet financial data million eur assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets incl prepaid expenses deferred taxes exceeding amount plan assets liquid funds current assets total assets equity liabilities december shareholders capital group reserves incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolling interests group equity difference capital consolidation provisions incl deferred taxes liabilities incl deferred income total liabilities incl deferred taxes deferred income total equity liabilities summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return equity equity ratio cash flow operating activities financial funds personnel expenses personnel expenses net sales average number employees research development expenses rd net sales investments tangible assets depreciation tangible assets p r n ch boehringer sohn ag co kg assets december binger strae intangible assets ingelheim rhein germany tangible assets telephone financial assets fax fixed assets contact inventories corporate division communications public affairs accounts receivable assets incl prepaid expenses matthias reinig deferred taxes exceeding amount plan assets email pressboehringeringelheimcom liquid funds internet wwwboehringeringelheimcom current assets issued total assets ch boehringer sohn ag co kg represented board managing directors hubertus von baumbach chair equity liabilities december carinne brouillon dr michel pairet shareholders capital jean scheftsik de szolnok michael schmelmer group reserves incl balance sheet currency conversion difference concept design layout group profit mpm corporate communication solutions mainz dsseldorf equity attributable parent company wwwmpmde noncontrolling interests photos group equity andreas reeg difference capital consolidation provisions incl deferred taxes printed eberl print gmbh immenstadt liabilities incl deferred income total liabilities incl deferred taxes deferred income copyright total equity liabilities ch boehringer sohn ag co kg rights reserved part annual report may reproduced transmitted form means summary selected financial data electronic photocopy without permission writing net sales ch boehringer sohn ag co kg figures third parties used annual report based data available operating income time financial statements drawn operating income net sales income taxes income taxes net sales return equity equity ratio cash flow operating activities financial funds personnel expenses carbon neutral personnel expenses net sales natureofficecom devebrj print production average number employees research development expenses rd net sales co emission certificates support forest conservation forest modification many regions germany investments tangible assets depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom